1
|
Garofalo M, Quintavalle C, Di Leva G, Zanca C, Romano G, Taccioli C, Liu CG, Croce CM, Condorelli G. Editorial Expression of Concern: MicroRNA signatures of TRAIL resistance in human non-small cell lung cancer. Oncogene 2024; 43:1075. [PMID: 38418545 DOI: 10.1038/s41388-024-02989-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/01/2024]
Affiliation(s)
- M Garofalo
- Department of Cellular and Molecular Biology and Pathology, University of Naples Federico II, Naples, Italy
- Istituto di Endocrinologia ed Oncologia Sperimentale, CNR, IEOS, Naples, Italy
- Department of Molecular Virology, Immunology and Medical Genetics, Human Cancer Genetics Program, Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA
| | - C Quintavalle
- Department of Cellular and Molecular Biology and Pathology, University of Naples Federico II, Naples, Italy
- Istituto di Endocrinologia ed Oncologia Sperimentale, CNR, IEOS, Naples, Italy
| | - G Di Leva
- Department of Molecular Virology, Immunology and Medical Genetics, Human Cancer Genetics Program, Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA
| | - C Zanca
- Department of Cellular and Molecular Biology and Pathology, University of Naples Federico II, Naples, Italy
- Istituto di Endocrinologia ed Oncologia Sperimentale, CNR, IEOS, Naples, Italy
| | - G Romano
- Department of Cellular and Molecular Biology and Pathology, University of Naples Federico II, Naples, Italy
- Istituto di Endocrinologia ed Oncologia Sperimentale, CNR, IEOS, Naples, Italy
| | - C Taccioli
- Department of Molecular Virology, Immunology and Medical Genetics, Human Cancer Genetics Program, Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA
| | - C G Liu
- Department of Molecular Virology, Immunology and Medical Genetics, Human Cancer Genetics Program, Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA
| | - C M Croce
- Department of Molecular Virology, Immunology and Medical Genetics, Human Cancer Genetics Program, Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA
| | - G Condorelli
- Department of Cellular and Molecular Biology and Pathology, University of Naples Federico II, Naples, Italy.
- Istituto di Endocrinologia ed Oncologia Sperimentale, CNR, IEOS, Naples, Italy.
- Facolta` di Scienze Biotecnologiche, University of Naples Federico II, Naples, Italy.
| |
Collapse
|
2
|
Sapienza M, Pavone V, Muscarà L, Panebianco P, Caldaci A, McCracken KL, Condorelli G, Caruso VF, Costa D, Di Giunta A, Testa G. Proximal humeral multiple fragment fractures in patients over 55: Comparison between Conservative treatment and Plate Fixation. Heliyon 2024; 10:e25898. [PMID: 38375257 PMCID: PMC10875435 DOI: 10.1016/j.heliyon.2024.e25898] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/16/2023] [Revised: 02/02/2024] [Accepted: 02/05/2024] [Indexed: 02/21/2024] Open
Abstract
Proximal humerus fractures account for about 5% of fragility fractures. These involve a significant burden of disability and a reduced quality of life. This study aims to compare functional results and surgical outcomes (closed reduction and internal fixation with the internal closure system of the proximal humerus) and the conservative management of proximal humerus fractures by 2-, 3-, 4-parts, in patients older than 55 years. Between January 2017 and April 2019, 65 patients with 2, 3 or 4-part fractures were retrospectively analyzed: 29 patients (5 males and 24 females) with an average age of 70.8 ± 9.9 years treated non-surgically (conservative group (CG)) and 36 patients (11 males and 25 females) with an average age of 66.2 ± 7.1 years treated surgically with plate fixation (operating group (OG)). Using different evaluation scores, we compared the OG and the CG. Through the DASH score we have seen how at 12 months there is a satisfactory result in patients with conservative treatment (p = 0.0019). Constant-Murley scale shows no difference between the two treatments (p = 0.2300). BARTHEL scale and SST score did not give statistically satisfactory results. Also, after one year of follow-up, patients treated with conservative therapy had a higher improvement in their Range of Motion (ROM) values than patients treated with surgical treatment. The results in terms of pain in NPRS at 3, 6, 12 months are better for conservative groups (p = 0,0000). Our findings suggest that conservative treatment in proximal humeral fractures, particularly in multi-fragmented fractures in patients over 55 years of age, designs an excellent alternative to the surgical option.
Collapse
Affiliation(s)
- Marco Sapienza
- Department of General Surgery and Medical Surgical Specialties, Section of Orthopaedics and Traumatology, P.O. “Policlinico Gaspare Rodolico”, University of Catania, Catania, Italy
| | - Vito Pavone
- Department of General Surgery and Medical Surgical Specialties, Section of Orthopaedics and Traumatology, P.O. “Policlinico Gaspare Rodolico”, University of Catania, Catania, Italy
| | - Liliana Muscarà
- Department of General Surgery and Medical Surgical Specialties, Section of Orthopaedics and Traumatology, P.O. “Policlinico Gaspare Rodolico”, University of Catania, Catania, Italy
| | - Pierpaolo Panebianco
- Department of General Surgery and Medical Surgical Specialties, Section of Orthopaedics and Traumatology, P.O. “Policlinico Gaspare Rodolico”, University of Catania, Catania, Italy
| | - Alessia Caldaci
- Department of General Surgery and Medical Surgical Specialties, Section of Orthopaedics and Traumatology, P.O. “Policlinico Gaspare Rodolico”, University of Catania, Catania, Italy
| | | | - Giuseppe Condorelli
- Department of General Surgery and Medical Surgical Specialties, Section of Orthopaedics and Traumatology, P.O. “Policlinico Gaspare Rodolico”, University of Catania, Catania, Italy
| | - Vincenzo Fabrizio Caruso
- Department of General Surgery and Medical Surgical Specialties, Section of Orthopaedics and Traumatology, P.O. “Policlinico Gaspare Rodolico”, University of Catania, Catania, Italy
| | - Danilo Costa
- Orthopaedic Division of Policlinico “G.B. Morgagni”, 95125, Catania, Italy
| | - Angelo Di Giunta
- Orthopaedic Division of Policlinico “G.B. Morgagni”, 95125, Catania, Italy
| | - Gianluca Testa
- Department of General Surgery and Medical Surgical Specialties, Section of Orthopaedics and Traumatology, P.O. “Policlinico Gaspare Rodolico”, University of Catania, Catania, Italy
| |
Collapse
|
3
|
Condello F, Rao S, Maurina M, Sturla M, Jolly S, Pancholy SB, Bertrand O, Lefevre T, Condorelli G, Stefanini GGS, Reimers B, Valgimigli M, Ferrante G. Effects of distal radial access vs conventional radial access in patients undergoing coronary angiography and/or intervention: a meta-analysis of randomised trials. Eur Heart J 2022. [DOI: 10.1093/eurheartj/ehac544.2053] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Background
Recently the distal radial access (DRA) technique has been introduced for coronary angiography and intervention as an alternative to the conventional radial access (RA).
Purpose
The aim of this study was to provide a quantitative appraisal of the effects of DRA vs conventional RA for coronary angiography with or without intervention.
Methods
The PubMed, Embase, Cochrane Central Register of Controlled Trials, and ClinicalTrials.gov databases were searched for randomised clinical trials (RCT) comparing DRA versus RA for coronary angiography and/or intervention. Data were pooled by meta-analysis using a random-effects model. The number of patients needed to treat for an additional beneficial outcome (NNTB) and the number needed to treat for an additional harmful outcome (NNTH) were calculated. The primary endpoint was radial artery occlusion (RAO) at the longest available follow-up. Additional secondary outcomes were assessed.
Results
A total of 13 RCT including 4,901 patients were identified and included in the final analysis. Coronary angiography alone was performed in 3 studies, percutaneous coronary intervention was performed in a variable proportion of patients ranging from 24% to 100% across studies. Study population included patients with chronic coronary syndrome in the large majority, and the proportion of acute coronary syndrome ranged from to 31% to 100% across studies. Compared with RA, DRA was associated with a significant lower risk of RAO, either detected at the longest follow-up (risk ratio [RR]: 0.36; 95% CI: 0.23 to 0.58; p<0.001, NNTB = 24.5), or in-hospital (RR: 0.32; 95% CI: 0.18 to 0.57; p<0.001, NNTB = 21.5), as well as Early discharge after transradial stenting of coronary arteries (EASY) Scale ≥ II hematoma (RR: 0.46; 95% CI: 0.22 to 0.97; p=0.04, NNTB = 66). By contrast, DRA was associated with a higher risk of access site crossover (RR: 3.43; 95% CI: 1.88 to 6.25, p<0.001, NNTH = 10), a longer time for radial artery puncture (standardized mean difference [SMD]: 3.56; 95% CI: 0.96 to 6.16; p<0.001), and sheath insertion (SMD: 0.38; 95% CI: 0.11 to 0.65, p=0.006), and a higher number of puncture attempts (SMD: 0.59, 95% CI: 0.48 to 0.69, p<0.001). A meta-regression analysis showed that increasing age in the RA group was associated with a reduced effect of DRA, compared with RA, on the risk of RAO. No significant effect of other variables such as the prevalence of female sex, diabetes, smoking status, acute coronary syndrome, and percutaneous coronary intervention was found.
Conclusions
Compared with RA, DRA is associated with lower risks of RAO and EASY ≥ II hematoma, but requires longer time for radial artery puncture and sheath insertion, more puncture attempts and a higher access site crossover.
Funding Acknowledgement
Type of funding sources: None.
Collapse
Affiliation(s)
- F Condello
- Humanitas Research Hospital , Milan , Italy
| | - S Rao
- Duke Clinical Research Institute, Cardiology , Durham , United States of America
| | - M Maurina
- Humanitas Research Hospital , Milan , Italy
| | - M Sturla
- Humanitas Research Hospital , Milan , Italy
| | - S Jolly
- Mcmaster University , Ontario , Canada
| | - S B Pancholy
- The Wright Center for Graduate Medical Education , Scranton , United States of America
| | - O Bertrand
- Quebec Heart and Lung Institute , Quebec , Canada
| | - T Lefevre
- Institut Cardiovasculaire Paris Sud , Paris , France
| | | | | | - B Reimers
- Humanitas Research Hospital , Milan , Italy
| | - M Valgimigli
- Cardiocentro Ticino Institute , Lugano , Switzerland
| | - G Ferrante
- Humanitas Research Hospital , Milan , Italy
| |
Collapse
|
4
|
Gitto M, Novelli L, Cozzi O, Reimers B, Condorelli G, Stefanini GG. Specific characteristics of STEMI in COVID-19 patients and their practical implications: a systematic review. Eur Heart J 2022. [PMCID: PMC9619531 DOI: 10.1093/eurheartj/ehac544.1424] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Introduction STEMI is one of the cardiac emergencies whose management has been mostly challenged by the COVID-19 pandemic. Patients presenting with the “lethal combo” of STEMI and concomitant SARS-CoV-2 infection have faced dramatic issues related to need for self-isolation, systemic inflammation with multi-organ disease, and difficulties to obtain timely diagnosis and treatment. Methods We performed a systematic search of three electronic databases from February 1st 2020 to January 31st 2022. We included all studies reporting crude rates of in-hospital outcomes of STEMI patients with concomitant COVID-19. Results A total of 9 observational studies were identified, mainly conducted during the first wave of the pandemic. STEMI patients with COVID −19 were more likely Afro-American and displayed higher rates of hypertension and diabetes with lower smoking prevalence. Associated comorbidities, including coronary artery disease, prior stroke and chronic kidney disease were also more common in those with SARS-CoV-2 infection. At coronary angiography, a higher thrombus burden in COVID-19 positive STEMI patients was highlighted, with up to 10-fold higher rates of stent thrombosis and greater need for glycoprotein IIb/IIa inhibitors and aspiration thrombectomy; this was not always associated with prolonged times from symptom onset to hospital admission and door-to-balloon. COVID-19 positive STEMI patients were less likely to receive coronary angiography and primary PCI, and more likely to be treated with fibrinolytics only. At the same time, patients with Covid-19 were more prone to present MINOCA. In-hospital mortality ranged from 15% to 40%, with consistent variability across different studies and subjects who tested positive for SARS-CoV-2 did also present higher rates of cardiogenic shock, cardiac arrest, prolonged ICU stay, mechanical ventilation, major bleeding, and stroke. Conclusion The coexistence of STEMI and COVID-19 was associated with increased in-hospital mortality and poor short-term prognosis. This was not entirely attributable to logistic issues determining delayed coronary revascularization, since patients' specific clinical and angiographic characteristics, including higher burden of cardiovascular risk factors and greater coronary thrombogenicity might have substantially contributed to this trend. Funding Acknowledgement Type of funding sources: None.
Collapse
Affiliation(s)
- M Gitto
- Humanitas Research Hospital , Milan , Italy
| | - L Novelli
- Humanitas Research Hospital , Milan , Italy
| | - O Cozzi
- Humanitas Research Hospital , Milan , Italy
| | - B Reimers
- Humanitas Research Hospital , Milan , Italy
| | | | | |
Collapse
|
5
|
Oliva A, Castiello D, Franzone A, Condorelli G, Colombo A, Esposito G, Stefanini G, Piccolo R. P2Y12 inhibitors monotherapy in patients undergoing complex vs. non-complex percutaneous coronary intervention: a meta-analysis of randomized trials. Eur Heart J 2022. [DOI: 10.1093/eurheartj/ehac544.1228] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background
Monotherapy with P2Y12 inhibitors (P2Y12i) is emerging as alternative strategy to dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI). However, early withdrawal of aspirin as part of P2Y12i monotherapy regimens may pose concerns in high-risk patients, such as those undergoing complex PCI.
Purpose
To evaluate the efficacy and safety of P2Y12i monotherapy after a short course of DAPT (1- to 3-month) compared with standard DAPT (≥12-month) according to PCI complexity.
Methods
We performed a meta-analysis of randomized trials using random effects models to combine hazard ratios (HRs) with 95% confidence intervals (CIs). No restrictions were applied to the type of P2Y12 receptor inhibitor (clopidogrel, prasugrel, or ticagrelor) or to the definition of complex PCI. Within-trial interactions were pooled to estimate heterogeneity between complex and noncomplex PCI strata. The study protocol was registered in the PROSPERO (CRD42021291027).
Results
We screened 7,502 unique citations, of which 2,948 were screened at title and abstract level and 576 were judged potentially eligible for full-text assessment. We included in the analysis five trials (1–5) enrolling 31,627 patients, of whom 8,328 (26.3%) underwent complex PCI; characteristics of trials and patient populations are summarized in Table 1. Risk estimates for efficacy and safety outcomes associated with P2Y12i monotherapy and standard DAPT across studies included in the analysis, stratified by complex and noncomplex PCI, are reported in Figure 1. P2Y12i monotherapy compared with standard DAPT was associated with a similar risk of all-cause death, stent thrombosis, and stroke, with no evidence for interaction between complex and noncomplex PCI. We found heterogeneity in the treatment effect of P2Y12i monotherapy vs. standard DAPT with respect to myocardial infarction (P-interaction=0.027). Compared with standard DAPT, P2Y12i monotherapy decreased the risk of myocardial infarction in complex PCI (HR 0.77, 95% CI 0.60–0.99, P=0.042), but not in noncomplex PCI patients (HR 1.09, 95% CI 0.90–1.30, P=0.382). The risk of major bleeding was significantly reduced by P2Y12i monotherapy with a consistent treatment effect (P-interaction=0.699) in both complex and noncomplex PCI strata.
Conclusions
Patients undergoing complex PCI may derive more benefit and less harm from P2Y12i monotherapy after early aspirin withdrawal compared with standard DAPT, resulting in decreased risks of myocardial infarction and bleeding.
Funding Acknowledgement
Type of funding sources: None.
Collapse
Affiliation(s)
- A Oliva
- Humanitas Research Hospital , Milan , Italy
| | - D Castiello
- Federico II University of Naples, Department of Advanced Biomedical Sciences , Naples , Italy
| | - A Franzone
- Federico II University of Naples, Department of Advanced Biomedical Sciences , Naples , Italy
| | | | - A Colombo
- Humanitas Research Hospital , Milan , Italy
| | - G Esposito
- Federico II University of Naples, Department of Advanced Biomedical Sciences , Naples , Italy
| | | | - R Piccolo
- Federico II University of Naples, Department of Advanced Biomedical Sciences , Naples , Italy
| |
Collapse
|
6
|
Bombace S, Maurina M, De Santis M, Motta F, Selmi C, Rodolfi S, Viggiani G, Gasparini G, Stefanini G, Condorelli G, Francone M, Monti L. CMR-driven immunosuppressive therapy in systemic sclerosis patients with suspected myocarditis: a single-center experience. Eur Heart J 2022. [DOI: 10.1093/eurheartj/ehac544.2635] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Background
Systemic sclerosis (SSc) myocarditis is common, but often underrecognized due to absence of symptoms at early stages. Cardiac Magnetic Resonance (CMR) is the imaging modality of choice for detection of SSc myocarditis. Current guidelines recommend CMR in case of alterations in first level cardiologic diagnostic tests. Immunosuppressive therapy is only indicated for patients with organ involvement, i.e. most frequently heart and lung, or with diffuse cutaneous systemic sclerosis.
Purpose
To explore the impact of CMR in the diagnostic and therapeutic pathway of SSc patients.
Methods
Of 286 SSc patients referred to our hospital, we retrospectively enrolled patients who received CMR during an observational period of 6 years (2016–2022). Exclusion criteria were previous immunosuppressive therapy and cardiopathy from other cause. Clinical data including Holter-ECG performed within 90 days from CMR were available.
Results
39 patients (67 [58–72] years; females 87%) were identified. 15 patients were excluded due to previous immunosuppressive therapy (9), lack of information on therapy (3), cardiopathy from other causes (3). 24 patients were finally included in the study.
14 patients (58%) did not show myocardial inflammation at CMR (LVEF 65.5 [61–69]%, LVEDV 114.5 [92–141] ml, T2 ratio 1.6 [1.4–1.9]). 1 patient presented with mid-wall inferior late gadolinium enhancement (LGE) indicative of previous myocarditis. 1 patient received immunosuppressive therapy due to SSc lung involvement in follow-up. In this group premature ventricular contractions (PVCs) during 24-hours Holter-ECG were rare (29 [3–48]). When measured, high-sensitivity Troponin I (hsTnI) was 2.4 [0.8–5] ng/L.
10 patients (42%) showed myocardial inflammation at CMR: LVEF 60 [56–65] %, LVEDV 137,5 [122–166] ml, T2 ratio 2.1 [1.7–2.3], T1 mapping 1022.5 [1010–1036] msec and T2 mapping 50.5 [50–52] msec. Myocardial LGE with non-ischemic pattern was seen in 6 patients. The number of PVCs at 24-hours Holter-ECG was collectively higher in these patients (354 [1–4245]). When measured, hsTnI was 8 [6–18] ng/L. With detection of myocardial inflammation at CMR all 10 patients eventually received immunosuppressive therapy (mycophenolate mofetil (MMF) or azathioprine in case of MMF intolerance).
At follow-up CMR performed 4 [3–6] months later on therapy various parameter differences were observed: LVEF (+2 [−2; 4] %), T1 mapping (−23 [−27; −12] msec), T2 mapping (−2 [−4; −1] msec), T2 ratio (−0.5 [−0.6; −0,2]). Of 6 patients with LGE, 4 displayed LGE persistence at follow-up.
Conclusions
In our experience, CMR was the tool of choice for diagnosis and therapeutic management in SSc patients with suspected cardiac involvement. SSc myocarditis patients tended to display more arrhythmic burden at Holter-ECG and higher cardiac biomarkers. Our data suggest to intensify first level cardiological screening, in order to identify suitable candidates to CMR.
Funding Acknowledgement
Type of funding sources: None.
Collapse
Affiliation(s)
- S Bombace
- Clinical Institute Humanitas IRCCS , Rozzano , Italy
| | - M Maurina
- Clinical Institute Humanitas IRCCS , Rozzano , Italy
| | - M De Santis
- Clinical Institute Humanitas IRCCS , Rozzano , Italy
| | - F Motta
- Clinical Institute Humanitas IRCCS , Rozzano , Italy
| | - C Selmi
- Clinical Institute Humanitas IRCCS , Rozzano , Italy
| | - S Rodolfi
- Clinical Institute Humanitas IRCCS , Rozzano , Italy
| | - G Viggiani
- University Hospital Rechts der Isar, Technical University of Munich , Munich , Germany
| | - G Gasparini
- Clinical Institute Humanitas IRCCS , Rozzano , Italy
| | - G Stefanini
- Clinical Institute Humanitas IRCCS , Rozzano , Italy
| | - G Condorelli
- Clinical Institute Humanitas IRCCS , Rozzano , Italy
| | - M Francone
- Clinical Institute Humanitas IRCCS , Rozzano , Italy
| | - L Monti
- Clinical Institute Humanitas IRCCS , Rozzano , Italy
| |
Collapse
|
7
|
Farina F, Serio S, Hall I, Zani S, Cassanmagnago G, Montserrat C, Civilini E, Condorelli G, Quintavalle M, Elia L. The epigenetic enzyme DOT1L orchestrates VSMC–monocyte crosstalk to protect against atherosclerosis via the NF-kB pathway. Atherosclerosis 2022. [DOI: 10.1016/j.atherosclerosis.2022.06.043] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
8
|
Bongiovanni D, Klug M, Scheibling E, Tsoy O, Louadi Z, Han J, Laugwitz KL, Condorelli G, List M, Bernlochner I. Beyond the prothrombotic transcript of RPs: alternative splicing and circular RNAs. Cardiovasc Res 2022. [DOI: 10.1093/cvr/cvac066.166] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Funding Acknowledgements
Type of funding sources: Foundation. Main funding source(s): German Center for Cardiovascular Research (DZHK)
Background/Introduction
RPs are young, hyper-reactive and RNA-rich platelets. They have a pro-thrombotic potential, are predictors of an insufficient response to antiplatelet therapy after myocardial infarction and are suggested to play a key role in patients with chronic coronary syndrome (CCS) and high on-treatment platelet reactivity. Moreover, RPs are promising novel biomarkers for the prediction of adverse cardiovascular events in different pathological settings.
Purpose
We aimed to compare for the first time the transcriptomic profiles of RPs and MPs in CCS patients.
Method
Using fluorescent activated cell sorting (FACS), we isolated RPs and MPs based on their RNA content from peripheral blood of 19 CCS patients. After sorting, RNA was extracted and quality, concentration and integrity were assessed with the Tapestation 4200 platform (Agilent). TotalRNA libraries were prepared, multiplexed and sequenced on a NextSeq 500 Illumina platform obtaining 80 to 100 million paired-end reads per sample. RNA-sequencing analysis was performed with R and DESeq2, a cut-off of p <0.005 and a log2fc >1 was applied. Alternative splicing event detection and analysis was performed with MAJIQ. We performed circular RNA (circRNA) analysis using CIRCexplorer.
Results
With total RNA-sequencing, we detected 1589 genes differentially expressed with 1100 transcripts upregulated in RPs, while 489 were enriched in MPs (Figure 1 A and B). In particular, transcripts for the collagen receptor GP6 (log2FC 1.12, p=6.89x10-41), thrombin receptor PAR4 (F2RL3, log2FC 1.1, p=3.54*10-21) and Von Willebrand Factor (log2FC 1.2, p value 1.26*10-38) were significantly enriched in RPs. We found an enrichment in MPs of transcript coding for genes involved in RNA processing such as the splicing regulator LUC7L3 (log2FC -1.01, p value 6.65*10-22). We detected several splicing events differentially regulated: an alternative splicing on the transcript GP6 is upregulated in RPs (Figure 1C); by the G-protein GNAQ transcript, one alternative splicing event was found upregulated in RPs, while two others were upregulated in MPs. Additionally, we detected an enrichment of the total level of circular RNAs in MPs compared to RPs (Figure 1E). Nevertheless, several circular RNAs that have not been described before were found enriched in RPs (Figure 1F).
Conclusion
This study represents the first transcriptomic profiling of RPs and MPs in patients with CCS and provides for the first time a biological explanation of RPs’ hyper-reactivity. The clear upregulation of prothrombotic signaling in RPs could provide and explanation to their hyperactivity and their correlation with cardiovascular events in different pathological settings. Altogether, these findings shed light on a new therapeutic niche in CCS patients. Nonetheless, the detrimental role of RPs in patients with coronary artery disease requires further investigations
Collapse
Affiliation(s)
- D Bongiovanni
- Hospital Rechts der Isar, I. Medizinische Klinik und Poliklinik , Munich , Germany
| | - M Klug
- Hospital Rechts der Isar, I. Medizinische Klinik und Poliklinik , Munich , Germany
| | - E Scheibling
- Hospital Rechts der Isar, I. Medizinische Klinik und Poliklinik , Munich , Germany
| | - O Tsoy
- Technical University of Munich, Experimental Bioinformatics, TUM School of Life Sciences Weihenstephan , Munich , Germany
| | - Z Louadi
- Technical University of Munich, Experimental Bioinformatics, TUM School of Life Sciences Weihenstephan , Munich , Germany
| | - J Han
- Hospital Rechts der Isar, I. Medizinische Klinik und Poliklinik , Munich , Germany
| | - KL Laugwitz
- Hospital Rechts der Isar, I. Medizinische Klinik und Poliklinik , Munich , Germany
| | - G Condorelli
- Clinical Institute Humanitas IRCCS, Department of Cardiovascular Medicine , Rozzano , Italy
| | - M List
- Technical University of Munich, Experimental Bioinformatics, TUM School of Life Sciences Weihenstephan , Munich , Germany
| | - I Bernlochner
- Hospital Rechts der Isar, I. Medizinische Klinik und Poliklinik , Munich , Germany
| |
Collapse
|
9
|
Robinson EL, Baker AH, Brittan M, McCracken I, Condorelli G, Emanueli C, Srivastava PK, Gaetano C, Thum T, Vanhaverbeke M, Angione C, Heymans S, Devaux Y, Pedrazzini T, Martelli F. Dissecting the transcriptome in cardiovascular disease. Cardiovasc Res 2022; 118:1004-1019. [PMID: 33757121 PMCID: PMC8930073 DOI: 10.1093/cvr/cvab117] [Citation(s) in RCA: 13] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/20/2020] [Accepted: 03/22/2021] [Indexed: 12/12/2022] Open
Abstract
The human transcriptome comprises a complex network of coding and non-coding RNAs implicated in a myriad of biological functions. Non-coding RNAs exhibit highly organized spatial and temporal expression patterns and are emerging as critical regulators of differentiation, homeostasis, and pathological states, including in the cardiovascular system. This review defines the current knowledge gaps, unmet methodological needs, and describes the challenges in dissecting and understanding the role and regulation of the non-coding transcriptome in cardiovascular disease. These challenges include poor annotation of the non-coding genome, determination of the cellular distribution of transcripts, assessment of the role of RNA processing and identification of cell-type specific changes in cardiovascular physiology and disease. We highlight similarities and differences in the hurdles associated with the analysis of the non-coding and protein-coding transcriptomes. In addition, we discuss how the lack of consensus and absence of standardized methods affect reproducibility of data. These shortcomings should be defeated in order to make significant scientific progress and foster the development of clinically applicable non-coding RNA-based therapeutic strategies to lessen the burden of cardiovascular disease.
Collapse
Affiliation(s)
- Emma L Robinson
- Department of Cardiology, Cardiovascular Research Institute Maastricht (CARIM), Universiteitssingel 50, 6229 Maastricht University, Maastricht, The Netherlands
- The Division of Cardiology, School of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, USA
| | - Andrew H Baker
- Centre for Cardiovascular Science, Queen’s Medical Research Institute, University of Edinburgh, 47 Little France Crescent, Edinburgh, EH16 4TJ, UK
| | - Mairi Brittan
- Centre for Cardiovascular Science, Queen’s Medical Research Institute, University of Edinburgh, 47 Little France Crescent, Edinburgh, EH16 4TJ, UK
| | - Ian McCracken
- Centre for Cardiovascular Science, Queen’s Medical Research Institute, University of Edinburgh, 47 Little France Crescent, Edinburgh, EH16 4TJ, UK
| | - G Condorelli
- Humanitas Research Hospital, Humanitas University, Via Manzoni 113, Rozzano, MI 20089, Italy
| | - C Emanueli
- Imperial College, National Heart and Lung Institute, Hammersmith campus, Du Cane Road, London W12 0NN, UK
| | - P K Srivastava
- Imperial College, National Heart and Lung Institute, Hammersmith campus, Du Cane Road, London W12 0NN, UK
| | - C Gaetano
- Laboratorio di Epigenetica, Istituti Clinici Scientifici Maugeri IRCCS, Via Maugeri 4, Pavia 27100, Italy
| | - T Thum
- Hannover Medical School, Institute of Molecular and Translational Therapeutic Strategies (IMTTS), Carl-Neuberg-Straße 1 30625 Hannover, Germany
| | - M Vanhaverbeke
- UZ Gasthuisberg Campus, KU Leuven, Herestraat 49 3000 Leuven, Belgium
| | - C Angione
- Department of Computer Science and Information Systems, Teesside University, Middlesbrough, TS4 3BX, UK
| | - S Heymans
- Department of Cardiology, Cardiovascular Research Institute Maastricht (CARIM), Universiteitssingel 50, 6229 Maastricht University, Maastricht, The Netherlands
| | - Y Devaux
- Cardiovascular Research Unit, Department of Population Health, Luxembourg Institute of Health, 1A-B, rue Thomas Edison, L-1445 Strassen, Luxembourg
| | - T Pedrazzini
- Experimental Cardiology Unit, Division of Cardiology, Department of Cardiovascular Medicine, University of Lausanne Medical School, 1011 Lausanne, Switzerland
| | - F Martelli
- Molecular Cardiology Laboratory, IRCCS-Policlinico San Donato, Piazza Edmondo Malan, 2, 20097 San Donato, Milan, Italy
| | | |
Collapse
|
10
|
Bongiovanni D, Klug M, Lazareva O, Kirmes K, Biasi M, Okrojek R, Gosetti R, Manz Q, Arend L, Bernett J, Von Scheidt M, Condorelli G, Laugwitz KL, List M, Bernlochner I. Reticulated platelet mass cytometry reveals unexplored therapeutic targets in patients with chronic coronary syndrome. Eur Heart J 2021. [DOI: 10.1093/eurheartj/ehab724.3375] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background
Reticulated platelets (RPs) are young, hyper-reactive thrombocytes that contain more RNA compared with mature platelets (MPs). The measurement of RPs level in peripheral blood with point-of-care systems is fast, reproducible, and inexpensive. Elevated RPs in peripheral blood predict adverse events in patients with acute and chronic coronary syndrome through unknown mechanisms. Preliminary transcriptome analyses reported an enrichment of pro-thrombotic transcripts. However, proteomic analyses are not available, and the biological features of RPs are largely unknown.
Purpose
We aimed to perform the largest proteomic characterization of RPs using mass cytometry with single-cell resolution in patients with chronic coronary syndrome (CCS) undergoing dual antiplatelet therapy (DAPT).
Methods
Thrombocytes from peripheral blood of CCS patients were isolated, prepared for mass cytometry (CyTOF) and stained with a custom-made CyTOF-panel of 20 antibodies targeting important transmembrane proteins (anti-CD9, anti-CD29, anti-CD31, anti-CD36-, anti-CD40, anti-CD41, anti-CD42a, anti-CD42b-, anti-CD47, anti-CD61, anti-CD62P-, anti-CD63, anti-CD69, anti-CD107a, anti-CD154, anti-GPVI, antiGPIIb/GPIIIa complex, anti-Par1, anti-PEAR-1 and the negative control anti-CD3 coupled with different metal isotopes). Two samples were prepared from each donor: one baseline sample (non-stimulated platelets) and one sample stimulated with 10 μM thrombin receptor-activating peptide (TRAP). According to previous experiences and common practice, we detected RPs and MPs based on their RNA content. We analyzed the results with a custom bioinformatic pipeline.
Results
13 patients with CCS on DAPT were included in this study. Mass cytometry highlighted an expression heterogeneity of relevant transmembrane proteins in thrombocytes of CCS patients (Figure 1A-B colored according to expression level: from blue-low to red-high). CyTOF detected an upregulation of important transmembrane receptors in RPs compared to MPs in quiescent platelets: GPVI (p<0.0001), PAR-1 (p<0.0001), GPIX (p<0.0001), and GPIbα (p<0.0001, Figure 1C). After TRAP-stimulation, RPs expressed higher levels of the activation markers P-Selectin (p=0.0016) and LAMP-3 (CD63, p<0.0001) compared to MPs confirming RPs hyperactivity (Figure 1D).
Conclusion
We here describe the first biological proteomic characterization with single-cell resolution of RPs biology in CCS patients. The upregulation of the activation markers P-Selectin and LAMP-3 as well as of specific transmembrane proteins as the collagen receptor GPVI and the thrombin receptor PAR-1 in patients treated with DAPT (schematic overview in Figure 2) provides the first solid biomolecular explanation of RPs hyper-reactivity and involvement in cardiovascular disease. Moreover, these results offer unexplored therapeutic targets to tailor antiplatelet therapy based on platelet protein expression in patients with elevated RPs
Funding Acknowledgement
Type of funding sources: Public grant(s) – National budget only. Main funding source(s): German Center for Cardiovascular Research (DZHK) Figure 1. Platelet expressionFigure 2. Schematic overview
Collapse
Affiliation(s)
- D Bongiovanni
- Hospital Rechts der Isar, I. Medizinische Klinik und Poliklinik, Munich, Germany
| | - M Klug
- Hospital Rechts der Isar, I. Medizinische Klinik und Poliklinik, Munich, Germany
| | - O Lazareva
- Technical University of Munich, Experimental Bioinformatics, TUM School of Life Sciences Weihenstephan, Munich, Germany
| | - K Kirmes
- Hospital Rechts der Isar, I. Medizinische Klinik und Poliklinik, Munich, Germany
| | - M Biasi
- Hospital Rechts der Isar, I. Medizinische Klinik und Poliklinik, Munich, Germany
| | - R Okrojek
- Hospital Rechts der Isar, I. Medizinische Klinik und Poliklinik, Munich, Germany
| | - R Gosetti
- Hospital Rechts der Isar, I. Medizinische Klinik und Poliklinik, Munich, Germany
| | - Q Manz
- Technical University of Munich, Experimental Bioinformatics, TUM School of Life Sciences Weihenstephan, Munich, Germany
| | - L Arend
- Technical University of Munich, Experimental Bioinformatics, TUM School of Life Sciences Weihenstephan, Munich, Germany
| | - J Bernett
- Technical University of Munich, Experimental Bioinformatics, TUM School of Life Sciences Weihenstephan, Munich, Germany
| | - M Von Scheidt
- Deutsches Herzzentrum Muenchen Technical University of Munich, Cardiology, Munich, Germany
| | - G Condorelli
- Clinical Institute Humanitas IRCCS, Department of Cardiovascular Medicine, Rozzano, Italy
| | - K L Laugwitz
- Hospital Rechts der Isar, I. Medizinische Klinik und Poliklinik, Munich, Germany
| | - M List
- Technical University of Munich, Experimental Bioinformatics, TUM School of Life Sciences Weihenstephan, Munich, Germany
| | - I Bernlochner
- Hospital Rechts der Isar, I. Medizinische Klinik und Poliklinik, Munich, Germany
| |
Collapse
|
11
|
Condello F, Cannata F, Sturla M, Pini D, Ferrante G, Condorelli G, Stefanini GG. Clinical effects of early sacubitril/valsartan administration in patients with ST-segment elevation myocardial infarction: a systematic review and meta-analysis. Eur Heart J 2021. [DOI: 10.1093/eurheartj/ehab724.1214] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Introduction
The combination of sacubitril, a neprilysin inhibitor and valsartan, an angiotensin receptor blocker, has been proven to be a game-changer in reducing morbidity and mortality in patients with chronic heart failure with reduced ejection fraction. Recent evidence regarding the early use of sacubutril/valsartan in patients after ST-segment Elevation Myocardial Infarction (STEMI) are emerging.
Purpose
To provide a comprehensive synthesis of effect estimates, we performed a systematic review and meta-analysis of randomized controlled trials (RCTs) directly comparing sacubitril/valsartan and an ACE-inhibitor early after successful primary percutaneous coronary intervention (pPCI) in patients presenting with STEMI
Methods
We searched the PubMed, EMBASE and Cochrane databases from inception to March 28, 2021 to identify RCTs that report clinical outcomes and compare sacubitril/valsartan versus an ACE-inhibitor in patients presenting with STEMI after pPCI. The primary efficacy endpoint was the risk of hospitalization for heart failure. Secondary efficacy endpoints were major adverse cardiac events (MACE) and left ventricle ejection fraction (LVEF). Safety endpoints were hypotension, hyperkalemia, worsening renal function and angioedema. Pooled risk ratios (RR) and mean differences (MD) with 95% confidence intervals (CIs) were used as summary statistics for endpoints of interest and were calculated using a random-effects model according to DerSimonian and Laird.
Results
A total of three studies with 493 patients randomly allocated to sacubitril/valsartan (n=247) or ACE-inhibitor (n=246) were included for analysis. Main study and patient characteristics are reported in figure1. Heterogeneity between studies was low. Individual trial definitions of MACE and adverse events were used in the analysis (figure 1). Sacubitril/valsartan was associated with a significant reduction in the risk of heart failure hospitalizations (RR, 0.55; 95% CI 0.39–0.79, P<0.01, event rate 15.4% vs 28.5%, number needed to treat 8), MACE (RR, 0.64; 95% CI, 0.48–0.84, P<0.01, event rate 20.2% vs 33.3%, number needed to treat 8), and with a significant improvement of LVEF (MD, 3.09; 95% CI, 1.70–4.49, P<0.01), (figure 2). No significant difference was found between sacubitril/valsartan and ACE-inhibitors regarding the incidence of hypotension (RR, 1.42; 95% CI, 0.74–2.72, P=0.29), hyperkalemia (RR, 0.44; 95% CI 0.06–3.08, P=0.41) and worsening renal function (RR, 0.70; 95% CI 0.22–2.24, P=0.55), (figure2). No angioedema was observed in included studies.
Conclusion
This is the first systematic review and meta-analysis comparing sacubitril/valsartan and ACE inhibitors in STEMI patients. Based on the presented findings and larger data on the horizon, we may soon find sacubitril/valsartan to be an important addition to our arsenal in improving care to STEMI patients.
Funding Acknowledgement
Type of funding sources: Public Institution(s). Main funding source(s): Italian Ministry of Education Figure 1Figure 2
Collapse
Affiliation(s)
- F Condello
- Humanitas Clinical and Research Center, Milan, Italy
| | - F Cannata
- Humanitas Clinical and Research Center, Milan, Italy
| | - M Sturla
- Humanitas University, Pieve Emanuele-Milan, Italy
| | - D Pini
- Humanitas Clinical and Research Center, Milan, Italy
| | - G Ferrante
- Humanitas Clinical and Research Center, Milan, Italy
| | - G Condorelli
- Humanitas Clinical and Research Center, Milan, Italy
| | - G G Stefanini
- Humanitas Clinical and Research Center, Milan, Italy
| |
Collapse
|
12
|
Pinto G, Villaschi A, Sanz-Sanchez J, Fazzari F, Regazzoli D, Mangieri A, Pini D, Bragato RM, Colombo A, Reimers B, Condorelli G, Stefanini GG, Chiarito M, Cannata F. Transcatheter aortic valve replacement in severe aortic stenosis and cardiac amyloidosis: a systematic review and meta-analysis. Eur Heart J 2021. [DOI: 10.1093/eurheartj/ehab724.1650] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
Background
Aortic stenosis (AS) and cardiac amyloidosis (CA) are typical degenerative diseases of the elderly. According to recent studies, up to 16% of patients referred to transcatheter aortic valve replacement (TAVR) have a concomitant diagnosis of CA. Until recently, TAVR in patients with CA and AS has been considered futile, following the results of small observational studies. However, few studies recently suggested a beneficial impact of TAVR in patients with AS and CA as compared with medical therapy alone.
Purpose
To clarify the efficacy and safety profile of TAVR in CA-AS patients.
Methods
We performed a systematic review and meta-analysis of studies evaluating the risk of mortality after TAVR in CA-AS patients as compared with medical therapy. Moreover, we performed a systematic review and descriptive meta-analysis of studies reporting outcomes and complication rates of TAVR in CA-AS patients as compared with patients with AS alone.
Results
We identified 4 observational studies reporting data on mortality in CA-AS patients treated with either TAVR or medical therapy. Mortality was significantly lower in patients undergoing TAVR (OR 0.23, 95% CI 0.07–0.73, I2=0%, NNT=2.6) as compared with medical therapy. A sensitivity analysis with hazard ratio as effect estimate showed consistent results. Then, we identified 4 observational studies reporting data on mortality, re-hospitalizations and periprocedural complications of TAVR in CA-AS patients as compared with patients with AS alone. We found higher rates of mortality, cardiovascular hospitalization and need for permanent pacemaker implantation in CA-AS patients as compared to lone AS patients undergoing TAVR. Conversely, no differences were found in terms of stroke, acute kidney injury and vascular complications.
Conclusions
Our analysis rejects the idea of futility of TAVR in CA-AS patients showing a clear survival benefit of CA-AS patients undergoing TAVR as compared with medical therapy. Moreover, these patients may undergo TAVR with an acceptable procedural risk, that is substantially comparable to lone AS patients, except for a higher incidence of permanent pacemaker implantation.
Funding Acknowledgement
Type of funding sources: None.
Collapse
Affiliation(s)
- G Pinto
- Humanitas University, Department of Biomedical Sciences, Pieve Emanuele - Milan, Italy
| | - A Villaschi
- Humanitas University, Department of Biomedical Sciences, Pieve Emanuele - Milan, Italy
| | - J Sanz-Sanchez
- Hospital Universitario y Politecnico La Fe, Valencia, Spain
| | - F Fazzari
- IRCCS Humanitas Research Hospital, Rozzano - Milano, Italy
| | - D Regazzoli
- IRCCS Humanitas Research Hospital, Rozzano - Milano, Italy
| | - A Mangieri
- IRCCS Humanitas Research Hospital, Rozzano - Milano, Italy
| | - D Pini
- IRCCS Humanitas Research Hospital, Rozzano - Milano, Italy
| | - R M Bragato
- IRCCS Humanitas Research Hospital, Rozzano - Milano, Italy
| | - A Colombo
- IRCCS Humanitas Research Hospital, Rozzano - Milano, Italy
| | - B Reimers
- IRCCS Humanitas Research Hospital, Rozzano - Milano, Italy
| | - G Condorelli
- Humanitas University, Department of Biomedical Sciences, Pieve Emanuele - Milan, Italy
| | - G G Stefanini
- Humanitas University, Department of Biomedical Sciences, Pieve Emanuele - Milan, Italy
| | - M Chiarito
- Humanitas University, Department of Biomedical Sciences, Pieve Emanuele - Milan, Italy
| | - F Cannata
- Humanitas University, Department of Biomedical Sciences, Pieve Emanuele - Milan, Italy
| |
Collapse
|
13
|
Pavone V, Vescio A, Denaro R, Costa D, Condorelli G, Caruso VF, Sessa G, Testa G. Use of different devices for surgical treatment of proximal humerus fractures in adults: a systematic review. Acta Biomed 2021; 92:e2021198. [PMID: 34487079 PMCID: PMC8477127 DOI: 10.23750/abm.v92i4.11394] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 02/25/2021] [Accepted: 03/23/2021] [Indexed: 11/23/2022]
Abstract
Background and aim: Proximal humeral fracture is one of the most common osteoporotic fractures in elderly people. The proper treatment choice is controversial. Open reduction and internal fixation (ORIF) with plate and screws is currently the most common treatment for the majority of displaced proximal humeral fractures. The aim of this systematic review is to investigate the surgical treatment outcomes of PHFs, focusing on main used devices and surgical approaches. Methods: From the earliest record up to 21 July 2020, two independent authors conducted a systematic review of two medical electronic database (PubMed and Science Direct). To achieve the maximum sensitivity of the search strategy, the following terms were combined: “(proximal NOT shaft NOT distal) AND humeral AND fracture AND (plate OR locking plate OR osteosynthesis NOT nail NOT arthroplasty)” as either key words or MeSH terms. The risk of bias of the included studies was assessed, agreeing to the Cochrane Handbook guidelines. Results: Thirty-four articles were initially noticed after the term string research in the two electronic databases. Finally, after full-text reading and analyzing the reference list, 8 studies were selected. The mean age recorded was 69.5 years (Range 67-72). All the studies included two-, three-, four-fragments fracture. Seven studies investigated PHILOS (Synthes, Bettlach, Switzerland) implants results, while one investigated CFR-PEEK plate (PEEK Power Humeral Fracture Plate; Arthrex, Naples, Florida, USA) outcomes or other plates. Deltopectoral and Transdeltoid approaches were the more common used. Conclusions: Both deltopectoral and transdeltoid approaches are valid approach in plating after proximal humerus fractures, for these reasons, the surgeon experience is crucial in the choice. The more valid implant is still unclear. The develop of prospective randomized comparative studies is strongly encourages. (www.actabiomedica.it)
Collapse
Affiliation(s)
- Vito Pavone
- Department of General Surgery and Medical Surgical Specialties, Section of Orthopaedics and Traumatology, University Hospital Policlinico-San Marco, University of Catania, Catania, Italy.
| | - Andrea Vescio
- Department of General Surgery and Medical Surgical Specialties, Section of Orthopaedics and Traumatology, University Hospital Policlinico-San Marco, University of Catania, Catania, Italy.
| | - Regina Denaro
- Department of General Surgery and Medical Surgical Specialties, Section of Orthopaedics and Traumatology, University Hospital Policlinico-San Marco, University of Catania, Catania, Italy.
| | - Danilo Costa
- Department of General Surgery and Medical Surgical Specialties, Section of Orthopaedics and Traumatology, University Hospital Policlinico-San Marco, University of Catania, Catania, Italy.
| | - Giuseppe Condorelli
- Department of General Surgery and Medical Surgical Specialties, Section of Orthopaedics and Traumatology, University Hospital Policlinico-San Marco, University of Catania, Catania, Italy.
| | - Vincenzo Fabrizio Caruso
- Department of General Surgery and Medical Surgical Specialties, Section of Orthopaedics and Traumatology, University Hospital Policlinico-San Marco, University of Catania, Catania, Italy.
| | - Giuseppe Sessa
- Department of General Surgery and Medical Surgical Specialties, Section of Orthopaedics and Traumatology, University Hospital Policlinico-San Marco, University of Catania, Catania, Italy.
| | - Gianluca Testa
- Department of General Surgery and Medical Surgical Specialties, Section of Orthopaedics and Traumatology, University Hospital Policlinico-San Marco, University of Catania, Catania, Italy.
| |
Collapse
|
14
|
Garofalo M, Quintavalle C, Di Leva G, Zanca C, Romano G, Taccioli C, Liu CG, Croce CM, Condorelli G. Correction: MicroRNA signatures of TRAIL resistance in human non-small cell lung cancer. Oncogene 2021; 40:1204. [PMID: 33398039 DOI: 10.1038/s41388-020-01608-1] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- M Garofalo
- Department of Cellular and Molecular Biology and Pathology, University of Naples Federico II, Naples, Italy.,Istituto di Endocrinologia ed Oncologia Sperimentale, CNR, IEOS, Naples, Italy.,Department of Molecular Virology, Immunology and Medical Genetics, Human Cancer Genetics Program, Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA
| | - C Quintavalle
- Department of Cellular and Molecular Biology and Pathology, University of Naples Federico II, Naples, Italy.,Istituto di Endocrinologia ed Oncologia Sperimentale, CNR, IEOS, Naples, Italy
| | - G Di Leva
- Department of Molecular Virology, Immunology and Medical Genetics, Human Cancer Genetics Program, Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA
| | - C Zanca
- Department of Cellular and Molecular Biology and Pathology, University of Naples Federico II, Naples, Italy.,Istituto di Endocrinologia ed Oncologia Sperimentale, CNR, IEOS, Naples, Italy
| | - G Romano
- Department of Cellular and Molecular Biology and Pathology, University of Naples Federico II, Naples, Italy.,Istituto di Endocrinologia ed Oncologia Sperimentale, CNR, IEOS, Naples, Italy
| | - C Taccioli
- Department of Molecular Virology, Immunology and Medical Genetics, Human Cancer Genetics Program, Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA
| | - C G Liu
- Department of Molecular Virology, Immunology and Medical Genetics, Human Cancer Genetics Program, Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA
| | - C M Croce
- Department of Molecular Virology, Immunology and Medical Genetics, Human Cancer Genetics Program, Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA
| | - G Condorelli
- Department of Cellular and Molecular Biology and Pathology, University of Naples Federico II, Naples, Italy. .,Istituto di Endocrinologia ed Oncologia Sperimentale, CNR, IEOS, Naples, Italy. .,Facoltàdi Scienze Biotecnologiche, University of Naples Federico II, Naples, Italy.
| |
Collapse
|
15
|
Ng CKY, Di Costanzo GG, Tosti N, Paradiso V, Coto-Llerena M, Roscigno G, Perrina V, Quintavalle C, Boldanova T, Wieland S, Marino-Marsilia G, Lanzafame M, Quagliata L, Condorelli G, Matter MS, Tortora R, Heim MH, Terracciano LM, Piscuoglio S. Genetic profiling using plasma-derived cell-free DNA in therapy-naïve hepatocellular carcinoma patients: a pilot study. Ann Oncol 2019; 29:1286-1291. [PMID: 29509837 DOI: 10.1093/annonc/mdy083] [Citation(s) in RCA: 68] [Impact Index Per Article: 13.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022] Open
Abstract
Background Hepatocellular carcinomas (HCCs) are not routinely biopsied, resulting in a lack of tumor materials for molecular profiling. Here we sought to determine whether plasma-derived cell-free DNA (cfDNA) captures the genetic alterations of HCC in patients who have not undergone systemic therapy. Patients and methods Frozen biopsies from the primary tumor and plasma were synchronously collected from 30 prospectively recruited, systemic treatment-naïve HCC patients. Deep sequencing of the DNA from the biopsies, plasma-derived cfDNA and matched germline was carried out using a panel targeting 46 coding and non-coding genes frequently altered in HCCs. Results In 26/30 patients, at least one somatic mutation was detected in biopsy and/or cfDNA. Somatic mutations in HCC-associated genes were present in the cfDNA of 63% (19/30) of the patients and could be detected 'de novo' without prior knowledge of the mutations present in the biopsy in 27% (8/30) of the patients. Mutational load and the variant allele fraction of the mutations detected in the cfDNA positively correlated with tumor size and Edmondson grade. Crucially, among the seven patients in whom the largest tumor was ≥5 cm or was associated with metastasis, at least one mutation was detected 'de novo' in the cfDNA of 86% (6/7) of the cases. In these patients, cfDNA and tumor DNA captured 87% (80/92) and 95% (87/92) of the mutations, suggesting that cfDNA and tumor DNA captured similar proportions of somatic mutations. Conclusion In patients with high disease burden, the use of cfDNA for genetic profiling when biopsy is unavailable may be feasible. Our results support further investigations into the clinical utility of cfDNA in a larger cohort of patients.
Collapse
Affiliation(s)
- C K Y Ng
- Institute of Pathology, University Hospital Basel, Basel; Hepatology Laboratory, Department of Biomedicine, University of Basel, Basel, Switzerland.
| | - G G Di Costanzo
- Department of Transplantation - Liver Unit, Cardarelli Hospital, Naples
| | - N Tosti
- Institute of Pathology, University Hospital Basel, Basel
| | - V Paradiso
- Institute of Pathology, University Hospital Basel, Basel
| | - M Coto-Llerena
- Hepatology Laboratory, Department of Biomedicine, University of Basel, Basel, Switzerland
| | - G Roscigno
- Department of Molecular Medicine and Medical Biotechnology, "Federico II" University of Naples, Naples, Italy
| | - V Perrina
- Institute of Pathology, University Hospital Basel, Basel
| | - C Quintavalle
- Institute of Pathology, University Hospital Basel, Basel
| | - T Boldanova
- Hepatology Laboratory, Department of Biomedicine, University of Basel, Basel, Switzerland; Division of Gastroenterology and Hepatology, University Hospital Basel, Basel, Switzerland
| | - S Wieland
- Hepatology Laboratory, Department of Biomedicine, University of Basel, Basel, Switzerland
| | | | - M Lanzafame
- Institute of Pathology, University Hospital Basel, Basel
| | - L Quagliata
- Institute of Pathology, University Hospital Basel, Basel
| | - G Condorelli
- Department of Molecular Medicine and Medical Biotechnology, "Federico II" University of Naples, Naples, Italy
| | - M S Matter
- Institute of Pathology, University Hospital Basel, Basel
| | - R Tortora
- Department of Transplantation - Liver Unit, Cardarelli Hospital, Naples
| | - M H Heim
- Hepatology Laboratory, Department of Biomedicine, University of Basel, Basel, Switzerland; Division of Gastroenterology and Hepatology, University Hospital Basel, Basel, Switzerland
| | | | - S Piscuoglio
- Institute of Pathology, University Hospital Basel, Basel.
| |
Collapse
|
16
|
Barandalla Sobrados M, Carullo P, Salvarani N, Condorelli G, Miragoli M, Catalucci D. 3072Myocardial delivery of therapeutic miR-133 via inhalable nanoparticles prevents the pathologic development in a model of ventricular pressure overload. Eur Heart J 2019. [DOI: 10.1093/eurheartj/ehz745.0028] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Background
MicroRNAs (miRs) are regulators involved in several biological processes and have been recognized as potential novel therapeutic targets for the treatment and prevention of CDs. We previously demonstrated that the cardiac-enriched miR-133, which is inversely related to failing heart conditions, is involved in several aspects of pathological cardiac remodeling via mitigation of cardiac hypertrophy and fibrosis, fine-tuning of the β1-adrenergic receptor signaling, and protection against oxidative stress-mediated apoptosis. However, effective and clinically oriented interventions aiming to delivery exogenous miR-133 for preventing the stress-induced downregulation of miR-133 levels are still missing.
Here, we applied an unconventional and effective nanotechnology-based inhalation approach enabling the delivery to diseased heart of exogenous miR-133 loaded into biocompatible and biodegradable calcium phosphate-based nanoparticles (CaPs).
Methods
Male C57Bl/6J mice (8 weeks) were subjected to a trans-aortic constriction (TAC), to induce a ventricular pressure overload. 4 experimental groups of TAC animals were randomly assigned to different intratracheal administrations of: 1. Saline (TAC Control); 2. CaP-miR133 (TAC CaP-miR133); 3. Pristine miR-133 (TAC miR133); 4. Unloaded CaPs (TAC CaP). Not TAC operated mice served as SHAM group. Intratracheal nebulizations were performed immediately after TAC surgery once-a-day in alternative days for 4 consecutive weeks. Echocardiography (ECO) were conducted before TAC, at 2 and 4 weeks after surgery. ECO as well as molecular and histological analyses were performed at sacrifices.
Results
ECO analyses showed an effective CaP-miR133-associated reversal of the failure progression, preserving left ventricular internal diameter (LVID) during cardiac cycle, ejection fraction (EF) and fraction shortening (FS), both at 2 and 4 weeks after TAC. This improvement was associated with the restoration of physiological levels of miR-133 in TAC-stressed isolated cardiomyocytes as well as its contractile activity. TAC mice receiving CaP-mir133 showed reduced indexes of fibrosis. In contrast, no beneficial effects were observed when unloaded CaPs or pristine miR-133 were administered. No major alterations of the immunological status of mice were observed after CaP-miR133 administration.
Conclusions
Intratracheal nebulization of miR-133-loaded nanoparticles is an effective approach for the beneficial restoration of cardiac performance, cell contractility and remodeling in a mouse model of left ventricular pressure overload. Providing the evidence for a potential innovative application of the emerging nanotechnologies, our approach might represent an important step forward for the treatment of cardiovascular diseases.
Acknowledgement/Funding
Fondazione Umberto Veronesi and CUPIDO project (EU's Horizon 2020, Grant Agreement 720834)
Collapse
Affiliation(s)
- M Barandalla Sobrados
- National Research Council-Institute of Genetic and Biomedical Research, Humanitas Clinical and Research Center, Milano, Italy
| | - P Carullo
- National Research Council-Institute of Genetic and Biomedical Research, Humanitas Clinical and Research Center, Milano, Italy
| | - N Salvarani
- National Research Council-Institute of Genetic and Biomedical Research, Humanitas Clinical and Research Center, Milano, Italy
| | - G Condorelli
- National Research Council-Institute of Genetic and Biomedical Research, Humanitas Clinical and Research Center, Humanitas University, Milano, Italy
| | - M Miragoli
- Humanitas Clinical and Research Center, Milano, University of Parma, Department of Medicine and Surgery, Parma, Italy
| | - D Catalucci
- National Research Council-Institute of Genetic and Biomedical Research, Humanitas Clinical and Research Center, Milano, Italy
| |
Collapse
|
17
|
Stefanini GG, Naci H, Cao D, Malanchini G, Sturla M, Byrne R, Baber U, Reimers B, Condorelli G, Mossialos E, Windecker S, Mehran R. P6138Quality of clinical trial evidence on devices and drugs approved to treat coronary artery disease. Eur Heart J 2019. [DOI: 10.1093/eurheartj/ehz746.0745] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Background
Regulatory approval of drugs and devices follow two different pathways. Whether different approval pathways underlie meaningful differences in quality of clinical trial evidence is unknown. We aimed to compare the quality of evidence of clinical trials that served as a basis for approval by the U.S. Food and Drug Administration (FDA) of drugs and devices used for the treatment of coronary artery disease.
Methods
FDA databases were searched for devices (i.e., coronary artery drug-eluting stents) and drugs (i.e., agents targeting atherothrombosis) approved between January 1st, 2001 and December 31st, 2017. FDA medical reviews were screened to identify trials that served for approval purposes. The pre-specified primary outcome was the prevalence of randomized trials used for approval (i.e. number of randomized trials/overall number of trials).
Results
A total of 97 trials were identified, 39 serving for approval of 13 devices and 58 serving for approval of 8 drugs. Devices were evaluated by fewer trials per item as compared with drugs (3.0±1.4 vs. 7.3±5.3, P=0.012) with similar study size (501 [100–1314] vs. 379 [183–904] patients per trial, P=0.55). Trials evaluating devices were less frequently randomized (56.4% vs. 94.8%, P<0.001) and more frequently designed powered for clinical endpoints (53.8% vs. 17.2%, P<0.001) as compared to those evaluating drugs. Use of randomization declined over time among trials supporting FDA approval of devices. In addition, significant differences were present between trials evaluating devices and those evaluating drugs in terms of study design, comparator used, blinding to treatment allocation, primary hypothesis, primary endpoint, and type of patients included.
Use of randomized trials for approval
Conclusions
There are substantial differences in clinical trial evidence serving for FDA approval of devices and drugs used for treatment of coronary artery disease. The lower degree of randomized evidence used for approval of devices as compared to drugs raises some concerns, particularly in view of its decline over time.
Collapse
Affiliation(s)
| | - H Naci
- London School of Economics and Political Science, LSE Health, Department of Health Policy, London, United Kingdom
| | - D Cao
- Humanitas University, Milan, Italy
| | | | - M Sturla
- Humanitas University, Milan, Italy
| | - R Byrne
- Deutsches Herzzentrum Muenchen Technical University of Munich, Munich, Germany
| | - U Baber
- Mount Sinai School of Medicine, New York, United States of America
| | - B Reimers
- Humanitas Clinical and Research Center - IRCCS, Milan, Italy
| | | | - E Mossialos
- London School of Economics and Political Science, LSE Health, Department of Health Policy, London, United Kingdom
| | - S Windecker
- Bern University Hospital, Department of Cardiology, Bern, Switzerland
| | - R Mehran
- Mount Sinai School of Medicine, New York, United States of America
| |
Collapse
|
18
|
Quintavalle C, Esposito C, Ingenito F, Affinito A, Roscigno G, Scognamiglio I, Nuzzo S, Catuogno S, Thomas R, Condorelli G. Aptamer-mediated exosomes detection for early breast cancer identification. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz269.023] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
19
|
Gigante B, Papa L, Bye A, Kunderfranco P, Viviani C, De Faire U, Briguori C, Bottai M, Condorelli G. P4154MicroRNA Signatures Predict Early Major Coronary Events in Middle Aged Men and Women. Eur Heart J 2019. [DOI: 10.1093/eurheartj/ehz745.0726] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
Background
The role of microRNA as biomarkers able to predict major coronary events (MACE) has not been fully elucidated, reproducibility being a critical issue.
Aim
To identify circulating microRNA signatures able to predict MACE.
Methods
We employed a PCR-based method to screen 754 microRNAs in a cohort of 60-year-olds (60YOs) from Stockholm, using a nested case-control design (100 cases vs 100 matched controls). The association of microRNAs and their interaction with the risk of MACE (myocardial infarction (MI), angina and sudden cardiac death) was estimated with random-effect logistic regression and expressed as OR with 95% CI. A bioinformatics approach identified microRNA clusters based on predicted targets. Main findings were tested in 58 MI and 60 age and sex matched referents from the the Nord-Trøndelag Health (HUNT) Study, a longitudinal population health study conducted in Norway.
Results
Fifty-five microRNAs were found to be associated with risk of MACE in the 60YO. MicroRNA-145-3p was associated with the largest estimated risk increase of MACE after adjustment for the common CV risk factors (OR: 2.18; 95% CI: 1.27–3.75). Interaction analysis revealed that increasing plasma levels of microRNA-320b modulated the association of 16 microRNAs with risk of MACE. As an example the estimated MACE risk associated with microRNA-145-3p was 1.47 (0.87–2.47) in the presence of low (<25th percentile) and 4.00 (1.79- 8.93) in the presence of high (>75th percentile) miRNA 320b expression levels. Sixteen microRNA pairs could be classified in 4 functional clusters with 492 predicted gene targets, mainly involved in the regulation of inflammation, thrombosis and lipid metabolism. Eight miRNAs interacting pairs belonging to cluster 2 and 4 showed a similar association trend with MI risk in the HUNT study.
Conclusions
We report the identification of microRNA signatures predicting risk of MACE in middle-aged Scandinavian men and women. These signatures could be a valuable tool to improve CV disease prediction in the aged.
Collapse
Affiliation(s)
- B Gigante
- Karolinska Institutet, Stockholm, Sweden
| | - L Papa
- Humanitas Clinical and Research Center – IRCCS, and Humanitas University, Cardiovascular Medicine, Milano, Italy
| | - A Bye
- Norwegian University of Science and Technology, Trondheim, Norway
| | - P Kunderfranco
- Humanitas Clinical and Research Center – IRCCS, and Humanitas University, Cardiovascular Medicine, Milano, Italy
| | - C Viviani
- Humanitas Clinical and Research Center – IRCCS, and Humanitas University, Cardiovascular Medicine, Milano, Italy
| | - U De Faire
- Karolinska Institutet, Stockholm, Sweden
| | | | - M Bottai
- Karolinska Institutet, Stockholm, Sweden
| | - G Condorelli
- Humanitas Clinical and Research Center – IRCCS, and Humanitas University, Cardiovascular Medicine, Milano, Italy
| |
Collapse
|
20
|
Affinito A, Quintavalle C, Esposito C, Roscigno G, Vilardo C, Nuzzo S, Ricci Vitiani L, De Luca G, Minic Z, Giannetti S, Pallini R, Berezovski M, Kichkailo A, Lapin I, De Franciscis V, Condorelli G. The discovery of RNA-aptamers that selectively bind and inhibit glioblastoma stem cells by targeting EphA2. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz269.016] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
21
|
Bongiovanni D, Santamaria G, Klug M, Santovito D, Felicetta A, Hristov M, Aslani M, Weber C, Peano C, Condorelli G, Laugwitz KL, Bernlochner I. 2181The prothrombotic transcriptome of reticulated platelets. Eur Heart J 2019. [DOI: 10.1093/eurheartj/ehz748.0100] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Introduction
Reticulated platelets (RPs) are young, hyper-reactive platelets that are larger and contain significantly more RNA compared to older mature platelets. High levels of RPs in peripheral blood are predictors of an insufficient response to dual antiplatelet therapy in cardiovascular patients and of adverse cardiovascular events also in non-cardiac patients. However, the mechanisms underlying these correlations remains widely unknown and the biology of RPs has not been investigated yet.
Purpose
We aimed to compare for the first time the transcriptomic profiles of RPs and mature platelets (MPs).
Methods
RPs and MPs from peripheral blood of healthy donors were identified and isolated using FACS/Sorting based on their RNA-content. Immediately after sorting, RNA was extracted and quality, concentration and integrity was assessed with the Tapestation 4200 platform (Agilent). Total- and small-RNA libraries were prepared, multiplexed and sequenced on a NextSeq 500 Illumina platform
Results
Total-RNA-sequencing revealed 1744 differentially expressed genes (670 downregulated 1074 upregulated) in RPs compared to MPs (Figure 1A, B). In particular, transcripts for the collagen receptor GP6, thromboxane receptor A2 (TBXA2R), thrombin receptor PAR4 (F2RL3) and ATP receptor P2RX1 were significantly enriched in RPs, whereas several RNA regulators as the ribonuclease PARN, the RISC-component TNRC6A and the splicing factor LUC7L3 were downregulated in RPs. Gene ontology analysis revealed an enrichment of relevant biological categories in RPs including platelet activation and blood coagulation (Figure 1C). Gene Set Enrichment Analysis showed an enrichment of several activation pathways like thrombin, thromboxane and GPIIb/IIIa signaling in RPs. Small-RNA-sequencing reported 9 miRNAs significantly downregulated in RPs with targets involved in platelet reactivity.
Figure 1
Conclusions
This study represents the first comparative transcriptome analysis of RPs and MPs and reports for the first time a differential enrichment of transcripts involved in platelet activation. The clear upregulation of prothrombotic signaling in RPs could explain, at least in part, their hyper-activity and their correlation with cardiovascular events in different pathological settings (trancripts enriched in RPs: Figure 1D).
Acknowledgement/Funding
German Society of Cardiology (DGK Nr.102018) ESC First conctact initiative grant 2018
Collapse
Affiliation(s)
- D Bongiovanni
- Hospital Rechts der Isar, Medical Department 1, Cardiology, Munich, Germany
| | - G Santamaria
- Hospital Rechts der Isar, Medical Department 1, Cardiology, Munich, Germany
| | - M Klug
- Hospital Rechts der Isar, Medical Department 1, Cardiology, Munich, Germany
| | - D Santovito
- Ludwig-Maximilians University, Institut für Prophylaxe und Epidemiologie der Kreislaufkrankheiten, Munich, Germany
| | - A Felicetta
- Clinical Institute Humanitas IRCCS, Department of Cardiovascular Medicine, Rozzano, Italy
| | - M Hristov
- Ludwig-Maximilians University, Institut für Prophylaxe und Epidemiologie der Kreislaufkrankheiten, Munich, Germany
| | - M Aslani
- Ludwig-Maximilians University, Institut für Prophylaxe und Epidemiologie der Kreislaufkrankheiten, Munich, Germany
| | - C Weber
- Ludwig-Maximilians University, Institut für Prophylaxe und Epidemiologie der Kreislaufkrankheiten, Munich, Germany
| | - C Peano
- National Research Council of Italy, Institute of Genetic and Biomedical Research, Rozzano, Italy
| | - G Condorelli
- Clinical Institute Humanitas IRCCS, Department of Cardiovascular Medicine, Rozzano, Italy
| | - K L Laugwitz
- Hospital Rechts der Isar, Medical Department 1, Cardiology, Munich, Germany
| | - I Bernlochner
- Hospital Rechts der Isar, Medical Department 1, Cardiology, Munich, Germany
| |
Collapse
|
22
|
Roscigno G, Quintavalle C, Affinito A, Cirella A, Cuccuru A, Thomas R, Condorelli G. Breast cancer organoids: A new tool for the prediction of drug penetration and patient outcome. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz269.022] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
23
|
Todaro M, Lombardo Y, Francipane MG, Alea MP, Cammareri P, Iovino F, Di Stefano AB, Di Bernardo C, Agrusa A, Condorelli G, Walczak H, Stassi G. Correction to: Apoptosis resistance in epithelial tumors is mediated by tumor-cell-derived interleukin-4. Cell Death Differ 2019; 26:2808-2809. [PMID: 31395960 DOI: 10.1038/s41418-019-0401-y] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022] Open
Abstract
Authors have only now noticed that in the Figure 3a, the immunohistochemical analysis of IL-4Rα on paraffin-embedded sections from breast is incorrect: IL-4 from breast was duplicated and used for the IL-4Rα staining. The correct Figure 3a has been included in the amendment to this paper.An amendment to this paper has been published and can be accessed via a link at the top of the paper.
Collapse
Affiliation(s)
- M Todaro
- Department of Surgical and Oncological Sciences, University of Palermo, Palermo, Italy
| | - Y Lombardo
- Department of Surgical and Oncological Sciences, University of Palermo, Palermo, Italy
| | - M G Francipane
- Department of Surgical and Oncological Sciences, University of Palermo, Palermo, Italy
| | - M Perez Alea
- Department of Surgical and Oncological Sciences, University of Palermo, Palermo, Italy
| | - P Cammareri
- Department of Genurto, University of Palermo, Palermo, Italy
| | - F Iovino
- Department of Surgical and Oncological Sciences, University of Palermo, Palermo, Italy
| | - A B Di Stefano
- Department of Surgical and Oncological Sciences, University of Palermo, Palermo, Italy
| | - C Di Bernardo
- Department of Genurto, University of Palermo, Palermo, Italy
| | - A Agrusa
- Department of Genurto, University of Palermo, Palermo, Italy
| | - G Condorelli
- Department of Cellular and Molecular Biology and Pathology, University of Naples 'Federico II', Naples, Italy
| | - H Walczak
- Division of Apoptosis Regulation, German Cancer Research Center (DKFZ), Heidelberg, Germany.
| | - G Stassi
- Department of Surgical and Oncological Sciences, University of Palermo, Palermo, Italy.
| |
Collapse
|
24
|
Pavone V, Testa G, Riccioli M, Di Stefano A, Condorelli G, Sessa G. Surgical treatment with cannulated screws for pediatric femoral neck fractures: A case series. Injury 2019; 50 Suppl 2:S40-S44. [PMID: 30770123 DOI: 10.1016/j.injury.2019.01.043] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
INTRODUCTION Femoral neck fractures are uncommon injuries in children, but the high incidence of long-term complications makes it important clinical entity. Early surgical treatment to achieve optimal results and to avoid a high rate of complications is widely advised. The purpose of this study was to retrospectively analyze the outcome of 8 children who sustained a femoral neck fracture. PATIENTS AND METHODS The patients (6 boys and 2 girls with an average age of 9.2 years) were treated within 24 h following admission to hospital by closed reduction and internal fixation. The type of fracture was distinguished according to Delbet's classification system. The outcome was analyzed using Ratliff's criteria, and a detailed record of complications was maintained. RESULTS According Delbet's classification system, there were 3 type I, 2 type II, 2 type III, and 1 type IV fractures. The average follow-up was 39.2 months (range 8-95). A satisfactory outcome was obtained in 6 (75%) children. Avascular necrosis was the most notable complication, which was reported in the 2 fair outcomes (25%). CONCLUSIONS Early and aggressive surgical treatment aimed at anatomical reduction result in a satisfactory outcome in pediatric femur neck fractures. Development of avascular necrosis is the main complication.
Collapse
Affiliation(s)
- Vito Pavone
- Department of Orthopaedics and Traumatologic Surgery, AOU Policlinico-Vittorio Emanuele, University of Catania, Catania, Italy.
| | - Gianluca Testa
- Department of Orthopaedics and Traumatologic Surgery, AOU Policlinico-Vittorio Emanuele, University of Catania, Catania, Italy
| | - Maria Riccioli
- Department of Orthopaedics and Traumatologic Surgery, AOU Policlinico-Vittorio Emanuele, University of Catania, Catania, Italy
| | - Antonio Di Stefano
- Department of Orthopaedics and Traumatologic Surgery, AOU Policlinico-Vittorio Emanuele, University of Catania, Catania, Italy
| | - Giuseppe Condorelli
- Department of Orthopaedics and Traumatologic Surgery, AOU Policlinico-Vittorio Emanuele, University of Catania, Catania, Italy
| | - Giuseppe Sessa
- Department of Orthopaedics and Traumatologic Surgery, AOU Policlinico-Vittorio Emanuele, University of Catania, Catania, Italy
| |
Collapse
|
25
|
Brown OI, Costanzo P, Clark AL, Condorelli G, Cleland JGF, Sathyapalan T, Hepburn D, Kilpatrick ES, Atkin SL. P4475Glycated haemoglobin and risk of all-cause, causal mortality and cardiovascular hospitalisation in type 2 diabetes mellitus according to body mass index. Eur Heart J 2018. [DOI: 10.1093/eurheartj/ehy563.p4475] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Affiliation(s)
- O I Brown
- University of Hull, Hull, United Kingdom
| | - P Costanzo
- University of Hull, Hull, United Kingdom
| | - A L Clark
- University of Hull, Hull, United Kingdom
| | - G Condorelli
- Clinical Institute Humanitas IRCCS, Rozzano, Italy
| | | | | | - D Hepburn
- University of Hull, Hull, United Kingdom
| | | | - S L Atkin
- Weill Cornell Medicine - Qata, Doha, Qatar
| |
Collapse
|
26
|
Malanchini G, Lombardi F, Condorelli G, Stefanini GG. 2399Weather conditions, pollution and incidence of acute coronary syndromes: a large-scale analysis of the italian national healthcare system administrative data. Eur Heart J 2018. [DOI: 10.1093/eurheartj/ehy565.2399] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Affiliation(s)
| | | | - G Condorelli
- Humanitas University, Department of Biomedical Sciences, Rozzano, Italy
| | - G G Stefanini
- Humanitas University, Department of Biomedical Sciences, Rozzano, Italy
| |
Collapse
|
27
|
Joris V, Metzinger T, Esfahani H, Balligand JL, Catalucci D, Condorelli G, Horman S, Dessy C. 9AMPKa1 participates in the regulation of miR199a to sustain cardiac hypertrophy. Cardiovasc Res 2018. [DOI: 10.1093/cvr/cvy060.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Affiliation(s)
- V Joris
- Institute of Experimental and Clinical Research (IREC), Pharmacolgy and therapeutics, Brussels, Belgium
| | - T Metzinger
- Institute of Experimental and Clinical Research (IREC), Pharmacolgy and therapeutics, Brussels, Belgium
| | - H Esfahani
- Institute of Experimental and Clinical Research (IREC), Pharmacolgy and therapeutics, Brussels, Belgium
| | - J L Balligand
- Institute of Experimental and Clinical Research (IREC), Pharmacolgy and therapeutics, Brussels, Belgium
| | - D Catalucci
- UOS of Milan and Humanitas Clinical and Research Center, Milan, Italy
| | - G Condorelli
- UOS of Milan and Humanitas Clinical and Research Center, Milan, Italy
| | - S Horman
- Institute of Experimental and Clinical Research (IREC), Cardiovascular Research Pole, Brussels, Belgium
| | - C Dessy
- Institute of Experimental and Clinical Research (IREC), Pharmacolgy and therapeutics, Brussels, Belgium
| |
Collapse
|
28
|
Malanchini G, Stefanini G, Panico C, Chiarito M, Cao D, Reimers B, Condorelli G. 2948Weather conditions and incidence of acute coronary syndromes: a large-scale analysis based on national healthcare system administrative data. Eur Heart J 2017. [DOI: 10.1093/eurheartj/ehx504.2948] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
29
|
Malanchini G, Stefanini G, Panico C, Cannata F, Briani M, Reimers B, Condorelli G. 1201Predictors of early recurrent events after acute coronary syndromes: a large-scale analysis based on National Healthcare System administrative data. Eur Heart J 2017. [DOI: 10.1093/eurheartj/ehx502.1201] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
30
|
Condorelli G, Elvira D, Danilo F, Giuseppina R, Martina N, Assunta A, Alessandra A, Cristina Q, Salvatore P, Rienzo A, Renato T. Abstract P4-03-12: Cancer-associated fibroblasts release exosomal microRNAs that dictate an aggressive phenotype in breast cancer. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p4-03-12] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
This abstract was not presented at the symposium.
Collapse
Affiliation(s)
- G Condorelli
- "Federico II” University, Naples, Naples, Italy; IRCCS-SDN, Naples, Italy; University of Basel, Dep of Pathology, Basel, Switzerland; Clinica Meditrerranea, Naples, Italy
| | - D Elvira
- "Federico II” University, Naples, Naples, Italy; IRCCS-SDN, Naples, Italy; University of Basel, Dep of Pathology, Basel, Switzerland; Clinica Meditrerranea, Naples, Italy
| | - F Danilo
- "Federico II” University, Naples, Naples, Italy; IRCCS-SDN, Naples, Italy; University of Basel, Dep of Pathology, Basel, Switzerland; Clinica Meditrerranea, Naples, Italy
| | - R Giuseppina
- "Federico II” University, Naples, Naples, Italy; IRCCS-SDN, Naples, Italy; University of Basel, Dep of Pathology, Basel, Switzerland; Clinica Meditrerranea, Naples, Italy
| | - N Martina
- "Federico II” University, Naples, Naples, Italy; IRCCS-SDN, Naples, Italy; University of Basel, Dep of Pathology, Basel, Switzerland; Clinica Meditrerranea, Naples, Italy
| | - A Assunta
- "Federico II” University, Naples, Naples, Italy; IRCCS-SDN, Naples, Italy; University of Basel, Dep of Pathology, Basel, Switzerland; Clinica Meditrerranea, Naples, Italy
| | - A Alessandra
- "Federico II” University, Naples, Naples, Italy; IRCCS-SDN, Naples, Italy; University of Basel, Dep of Pathology, Basel, Switzerland; Clinica Meditrerranea, Naples, Italy
| | - Q Cristina
- "Federico II” University, Naples, Naples, Italy; IRCCS-SDN, Naples, Italy; University of Basel, Dep of Pathology, Basel, Switzerland; Clinica Meditrerranea, Naples, Italy
| | - P Salvatore
- "Federico II” University, Naples, Naples, Italy; IRCCS-SDN, Naples, Italy; University of Basel, Dep of Pathology, Basel, Switzerland; Clinica Meditrerranea, Naples, Italy
| | - A Rienzo
- "Federico II” University, Naples, Naples, Italy; IRCCS-SDN, Naples, Italy; University of Basel, Dep of Pathology, Basel, Switzerland; Clinica Meditrerranea, Naples, Italy
| | - T Renato
- "Federico II” University, Naples, Naples, Italy; IRCCS-SDN, Naples, Italy; University of Basel, Dep of Pathology, Basel, Switzerland; Clinica Meditrerranea, Naples, Italy
| |
Collapse
|
31
|
Quintavalle C, Incoronato M, Puca L, Acunzo M, Zanca C, Romano G, Garofalo M, Iaboni M, Croce CM, Condorelli G. c-FLIPL enhances anti-apoptotic Akt functions by modulation of Gsk3β activity. Cell Death Differ 2017; 24:1134. [PMID: 28106885 DOI: 10.1038/cdd.2017.7] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022] Open
Abstract
This corrects the article DOI: 10.1038/cdd.2010.65.
Collapse
|
32
|
Pavone V, de Cristo C, Cannavò L, Testa G, Buscema A, Condorelli G, Sessa G. Midterm results of surgical treatment of displaced proximal humeral fractures in children. Eur J Orthop Surg Traumatol 2016; 26:461-7. [PMID: 27151160 DOI: 10.1007/s00590-016-1773-z] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/27/2016] [Accepted: 04/24/2016] [Indexed: 10/21/2022]
Abstract
PURPOSE To analyse the clinical outcomes of 26 children treated surgically for displaced proximal humerus fracture. MATERIALS AND METHODS From January 2008 to December 2012, 26 children/adolescents (14 boys, 12 girls) were treated surgically for displaced fractures at the proximal extremity of the humerus. Ten were grade III and 16 were grade IV according to the Neer-Horowitz classification with a mean age of 12.8 ± 4.2 years. Twenty young patients were surgically treated with a closed reduction and direct percutaneous pinning; six required an open approach. To obtain a proper analysis, we compared the Costant scores with the contralateral shoulder (Δ Costant). RESULTS The mean follow-up period was 34 months (range 10-55). Two grade IV patients showed a loss in the reduction after percutaneous treatment. This required open surgery with a plate and screws. On average, the treated fractures healed at 40 days. The mean Δ Costant score was 8.43 (range 2-22). There was a statistically significant improvement in the mean Δ Costant score in grade III patients. In grade IV patients, there was a significant improvement in the mean Δ Costant score in those treated with open surgery versus mini-invasive surgery. CONCLUSIONS Our study shows excellent results with percutaneous k-wires. This closed surgery had success in these patients, and the excellent outcomes noted here lead us to prefer the mini-invasive surgical approach in NH grade III fractures. In grade IV, the best results were noted in patients treated with open surgery. We suggest an open approach for these patients. LEVEL OF EVIDENCE III.
Collapse
Affiliation(s)
- Vito Pavone
- Orthopaedic Clinic, AOU Policlinico- Vittorio Emanuele, University of Catania, Catania, Italy.
| | - Claudia de Cristo
- Orthopaedic Clinic, AOU Policlinico- Vittorio Emanuele, University of Catania, Catania, Italy
| | - Luca Cannavò
- Orthopaedic Clinic, AOU Policlinico- Vittorio Emanuele, University of Catania, Catania, Italy
| | - Gianluca Testa
- Orthopaedic Clinic, AOU Policlinico- Vittorio Emanuele, University of Catania, Catania, Italy
| | - Antonio Buscema
- Orthopaedic Clinic, AOU Policlinico- Vittorio Emanuele, University of Catania, Catania, Italy
| | - Giuseppe Condorelli
- Orthopaedic Clinic, AOU Policlinico- Vittorio Emanuele, University of Catania, Catania, Italy
| | - Giuseppe Sessa
- Orthopaedic Clinic, AOU Policlinico- Vittorio Emanuele, University of Catania, Catania, Italy
| |
Collapse
|
33
|
Pavone V, Testa G, Restivo DA, Cannavò L, Condorelli G, Portinaro NM, Sessa G. Botulinum Toxin Treatment for Limb Spasticity in Childhood Cerebral Palsy. Front Pharmacol 2016; 7:29. [PMID: 26924985 PMCID: PMC4759702 DOI: 10.3389/fphar.2016.00029] [Citation(s) in RCA: 25] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/28/2015] [Accepted: 02/03/2016] [Indexed: 12/18/2022] Open
Abstract
CP is the most common cause of chronic disability in childhood occurring in 2–2.5/1000 births. It is a severe disorder and a significant number of patients present cognitive delay and difficulty in walking. The use of botulinum toxin (BTX) has become a popular treatment for CP especially for spastic and dystonic muscles while avoiding deformity and pain. Moreover, the combination of physiotherapy, casting, orthotics and injection of BTX may delay or decrease the need for surgical intervention while reserving single-event, multi-level surgery for fixed musculotendinous contractures and bony deformities in older children. This report highlights the utility of BTX in the treatment of cerebral palsy in children. We include techniques for administration, side effects, and possible resistance as well as specific use in the upper and lower limbs muscles.
Collapse
Affiliation(s)
- Vito Pavone
- Dipartimento di Chirurgia Generale e Specialità Medico-chirurgiche, Sez. Ortopedia, Azienda Ospedaliera Universitaria Policlinico-Vittorio Emanuele Catania, Italy
| | - Gianluca Testa
- Dipartimento di Chirurgia Generale e Specialità Medico-chirurgiche, Sez. Ortopedia, Azienda Ospedaliera Universitaria Policlinico-Vittorio Emanuele Catania, Italy
| | - Domenico A Restivo
- Neurologic Unit, Department of Internal Medicine, Nuovo "Garibaldi" Hospital Catania, Italy
| | - Luca Cannavò
- Dipartimento di Chirurgia Generale e Specialità Medico-chirurgiche, Sez. Ortopedia, Azienda Ospedaliera Universitaria Policlinico-Vittorio Emanuele Catania, Italy
| | - Giuseppe Condorelli
- Dipartimento di Chirurgia Generale e Specialità Medico-chirurgiche, Sez. Ortopedia, Azienda Ospedaliera Universitaria Policlinico-Vittorio Emanuele Catania, Italy
| | - Nicola M Portinaro
- Humanitas Clinical and Research Center, Clinica Ortopedica e Traumatologica Milan, Italy
| | - Giuseppe Sessa
- Dipartimento di Chirurgia Generale e Specialità Medico-chirurgiche, Sez. Ortopedia, Azienda Ospedaliera Universitaria Policlinico-Vittorio Emanuele Catania, Italy
| |
Collapse
|
34
|
Di Pasquale E, Salvarani N, Kunderfranco P, Crasto S, Miragoli M, Nakahama H, Rutigliano L, Carullo P, Forni F, Faggian G, Condorelli G. Generation of Ipsc-based cardiac models to investigate mechanisms of dilated cardiomyopathy due to Lamin A/C mutations. Vascul Pharmacol 2015. [DOI: 10.1016/j.vph.2015.11.027] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
35
|
Rusconi F, Ceriotti P, Miragoli M, Di Pasquale E, Carullo P, Salvarani N, Rocchetti M, Rossi S, Lodola F, Caprari S, Viggiani G, Cazade M, Kunderfranco P, Chemin J, Bang M, Polticelli F, Zaza A, Napolitano C, Priori S, Condorelli G, Catalucci D. Therapeutic modulation of cardiac function by selective peptidomimetic-mediated targeting of the l-type calcium channel machinery. Vascul Pharmacol 2015. [DOI: 10.1016/j.vph.2015.11.065] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
36
|
Cattaneo P, Kunderfranco P, Greco C, Guffanti A, Stirparo GG, Rusconi F, Rizzi R, Di Pasquale E, Locatelli SL, Latronico MVG, Bearzi C, Papait R, Condorelli G. DOT1L-mediated H3K79me2 modification critically regulates gene expression during cardiomyocyte differentiation. Cell Death Differ 2014; 23:555-64. [PMID: 25526092 DOI: 10.1038/cdd.2014.199] [Citation(s) in RCA: 44] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/23/2014] [Revised: 10/02/2014] [Accepted: 10/06/2014] [Indexed: 11/09/2022] Open
Abstract
Epigenetic changes on DNA and chromatin are implicated in cell differentiation and organogenesis. For the heart, distinct histone methylation profiles were recently linked to stage-specific gene expression programs during cardiac differentiation in vitro. However, the enzymes catalyzing these modifications and the genes regulated by them remain poorly defined. We therefore decided to identify the epigenetic enzymes that are potentially involved in cardiomyogenesis by analyzing the expression profile of the 85 genes encoding the epigenetic-related proteins in mouse cardiomyocytes (CMs), and then study how they affect gene expression during differentiation and maturation of this cell type. We show here with gene expression screening of epigenetic enzymes that the highly expressed H3 methyltransferase disruptor of telomeric silencing 1-like (DOT1L) drives a transitional pattern of di-methylation on H3 lysine 79 (H3K79) in CMs at different stages of differentiation in vitro and in vivo. Through a genome-wide chromatin-immunoprecipitation DNA-sequencing approach, we found H3K79me2 enriched at genes expressed during cardiac differentiation. Moreover, knockdown of Dot1L affected the expression of H3K79me2-enriched genes. Our results demonstrate that histone methylation, and in particular DOT1L-mediated H3K79me2 modification, drives cardiomyogenesis through the definition of a specific transcriptional landscape.
Collapse
Affiliation(s)
- P Cattaneo
- Laboratory of Cardiovascular Research, Humanitas Clinical and Research Center, Rozzano, Milan 20089, Italy.,Operational Unit of Milan, Institute of Genetics and Biomedical Research, National Research Council of Italy (CNR), Rozzano, Milan 20089, Italy.,Department of Biomedical Technologies and Translational Medicine, University of Milan, Milan 20133, Italy
| | - P Kunderfranco
- Laboratory of Cardiovascular Research, Humanitas Clinical and Research Center, Rozzano, Milan 20089, Italy
| | - C Greco
- Laboratory of Cardiovascular Research, Humanitas Clinical and Research Center, Rozzano, Milan 20089, Italy
| | - A Guffanti
- GenOmnia, via Nerviano 31/b, Lainate, Milan, 20020, Italy
| | - G G Stirparo
- Operational Unit of Milan, Institute of Genetics and Biomedical Research, National Research Council of Italy (CNR), Rozzano, Milan 20089, Italy.,Department of Biomedical Technologies and Translational Medicine, University of Milan, Milan 20133, Italy
| | - F Rusconi
- Laboratory of Cardiovascular Research, Humanitas Clinical and Research Center, Rozzano, Milan 20089, Italy
| | - R Rizzi
- Casa di Cura Multimedica Istituto di Ricovero Cura Carattere Scientifico, Milan 20138, Italy.,Institute of Cell Biology and Neurobiology, National Research Council of Italy (CNR), Rome 00100, Italy
| | - E Di Pasquale
- Laboratory of Cardiovascular Research, Humanitas Clinical and Research Center, Rozzano, Milan 20089, Italy.,Operational Unit of Milan, Institute of Genetics and Biomedical Research, National Research Council of Italy (CNR), Rozzano, Milan 20089, Italy
| | - S L Locatelli
- Operational Unit of Milan, Institute of Genetics and Biomedical Research, National Research Council of Italy (CNR), Rozzano, Milan 20089, Italy.,Department of Biomedical Technologies and Translational Medicine, University of Milan, Milan 20133, Italy
| | - M V G Latronico
- Laboratory of Cardiovascular Research, Humanitas Clinical and Research Center, Rozzano, Milan 20089, Italy
| | - C Bearzi
- Casa di Cura Multimedica Istituto di Ricovero Cura Carattere Scientifico, Milan 20138, Italy.,Institute of Cell Biology and Neurobiology, National Research Council of Italy (CNR), Rome 00100, Italy
| | - R Papait
- Laboratory of Cardiovascular Research, Humanitas Clinical and Research Center, Rozzano, Milan 20089, Italy.,Operational Unit of Milan, Institute of Genetics and Biomedical Research, National Research Council of Italy (CNR), Rozzano, Milan 20089, Italy
| | - G Condorelli
- Laboratory of Cardiovascular Research, Humanitas Clinical and Research Center, Rozzano, Milan 20089, Italy.,Operational Unit of Milan, Institute of Genetics and Biomedical Research, National Research Council of Italy (CNR), Rozzano, Milan 20089, Italy.,Department of Biomedical Technologies and Translational Medicine, University of Milan, Milan 20133, Italy
| |
Collapse
|
37
|
Fernandez S, Risolino M, Mandia N, Talotta F, Soini Y, Incoronato M, Condorelli G, Banfi S, Verde P. miR-340 inhibits tumor cell proliferation and induces apoptosis by targeting multiple negative regulators of p27 in non-small cell lung cancer. Oncogene 2014; 34:3240-50. [PMID: 25151966 PMCID: PMC4724947 DOI: 10.1038/onc.2014.267] [Citation(s) in RCA: 145] [Impact Index Per Article: 14.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/15/2014] [Revised: 06/29/2014] [Accepted: 07/14/2014] [Indexed: 12/19/2022]
Abstract
MicroRNAs (miRNAs) control cell cycle progression by targeting the transcripts encoding for cyclins, CDKs and CDK inhibitors, such as p27KIP1 (p27). p27 expression is controlled by multiple transcriptional and posttranscriptional mechanisms, including translational inhibition by miR-221/222 and posttranslational regulation by the SCFSKP2 complex. The oncosuppressor activity of miR-340 has been recently characterized in breast, colorectal and osteosarcoma tumor cells. However, the mechanisms underlying miR-340-induced cell growth arrest have not been elucidated. Here we describe miR-340 as a novel tumor suppressor in non-small cell lung cancer (NSCLC). Starting from the observation that the growth-inhibitory and proapoptotic effects of miR-340 correlate with the accumulation of p27 in lung adenocarcinoma and glioblastoma cells, we have analyzed the functional relationship between miR-340 and p27 expression. miR-340 targets three key negative regulators of p27. The miR-340-mediated inhibition of both Pumilio-family RNA-binding proteins (PUM1 and PUM2), required for the miR-221/222 interaction with the p27 3′UTR, antagonizes the miRNA-dependent downregulation of p27. At the same time, miR-340 induces the stabilization of p27 by targeting SKP2, the key posttranslational regulator of p27. Therefore, miR-340 controls p27 at both translational and posttranslational levels. Accordingly, the inhibition of either PUM1 or SKP2 partially recapitulates the miR-340 effect on cell proliferation and apoptosis. In addition to the effect on tumor cell proliferation, miR-340 also inhibits intercellular adhesion and motility in lung cancer cells. These changes correlate with the miR-340-mediated inhibition of previously validated (MET and ROCK1) and potentially novel (RHOA and CDH1) miR-340 target transcripts. Finally, we show that in a small cohort of NSCLC patients (n=23), representative of all four stages of lung cancer, miR-340 expression inversely correlates with clinical staging, thus suggesting that miR-340 downregulation contributes to the disease progression.
Collapse
Affiliation(s)
- S Fernandez
- CNR Institute of Genetics and Biophysics, Naples, Italy
| | - M Risolino
- CNR Institute of Genetics and Biophysics, Naples, Italy
| | - N Mandia
- CNR Institute of Genetics and Biophysics, Naples, Italy
| | - F Talotta
- CNR Institute of Genetics and Biophysics, Naples, Italy
| | - Y Soini
- Institute of Clinical Medicine, Pathology and Forensic Medicine, School of Medicine, Cancer Center of Eastern Finland, University of Eastern Finland, Kuopio, Finland
| | | | - G Condorelli
- Department of Cellular and Molecular Biology and Pathology, ''Federico II'' University of Naples, Naples, Italy
| | - S Banfi
- Telethon Institute of Genetics and Medicine (TIGEM), Naples, Italy
| | - P Verde
- 1] CNR Institute of Genetics and Biophysics, Naples, Italy [2] IRCCS SDN, Naples, Italy
| |
Collapse
|
38
|
Stirparo GG, Greco CM, Kunderfranco P, Carullo P, Serio S, Papait R, Condorelli G. P61Identification of temporally modulated lncRNAs in cardiac hypertrophy. Cardiovasc Res 2014. [DOI: 10.1093/cvr/cvu082.5] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
39
|
Di Pasquale E, Nakahama H, Kunderfranco P, Miragoli M, Forni A, Roncarati R, Carullo P, Faggian G, Condorelli G. 265Generation of iPSC-based cardiomyocytes for investigating mechanisms of dilated cardiomyopathy due to Lamin A/C mutations. Cardiovasc Res 2014. [DOI: 10.1093/cvr/cvu083.1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
40
|
Climent Salarich M, Condorelli G, Elia L. 273Cell to cell communication: miRNA involvement. Cardiovasc Res 2014. [DOI: 10.1093/cvr/cvu084.3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
41
|
Kunderfranco P, Cattaneo P, Greco CM, Carullo P, Stirparo GG, Rusconi F, Hasenfuss G, Chen J, Condorelli G, Papait R. P59An epigenetic signature regulates gene expression in cardiac hypertrophy. Cardiovasc Res 2014. [DOI: 10.1093/cvr/cvu082.3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
42
|
Greco CM, Kunderfranco P, Carullo P, Papait R, Condorelli G. P356Dynamic nature of the methylation landscape of the heart. Cardiovasc Res 2014. [DOI: 10.1093/cvr/cvu091.40] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
43
|
Høydal MA, Stølen TO, Johnsen AB, Alvez M, Catalucci D, Condorelli G, Koch LG, Britton SL, Smith GL, Wisløff U. Reduced aerobic capacity causes leaky ryanodine receptors that trigger arrhythmia in a rat strain artificially selected and bred for low aerobic running capacity. Acta Physiol (Oxf) 2014; 210:854-64. [PMID: 24444142 DOI: 10.1111/apha.12238] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/19/2013] [Revised: 09/05/2013] [Accepted: 01/12/2014] [Indexed: 11/27/2022]
Abstract
AIM Rats selectively bred for inborn low capacity of running (LCR) display a series of poor health indices, whereas rats selected for high capacity of running (HCR) display a healthy profile. We hypothesized that selection of low aerobic capacity over generations leads to a phenotype with increased diastolic Ca(2+) leak that trigger arrhythmia. METHODS We used rats selected for HCR (N = 10) or LCR (N = 10) to determine the effect of inborn aerobic capacity on Ca(2+) leak and susceptibility of ventricular arrhythmia. We studied isolated Fura-2/AM-loaded cardiomyocytes to detect Ca(2+) handling and function on an inverted epifluorescence microscope. To determine arrhythmogenicity, we did a final experiment with electrical burst pacing in Langendorff-perfused hearts. RESULTS Ca(2+) handling was impaired by reduced Ca(2+) amplitude, prolonged time to 50% Ca(2+) decay and reduced sarcoplasmic reticulum (SR) Ca(2+) content. Impaired Ca(2+) removal was influenced by reduced SR Ca(2+) ATP-ase 2a (SERCA2a) function and increased sodium/Ca(2+) exchanger (NCX) in LCR rats. Diastolic Ca(2) leak was 87% higher in LCR rats. The leak was reduced by CaMKII inhibition. Expression levels of phosphorylated threonine 286 CaMKII levels and increased RyR2 phosphorylation at the serine 2814 site mechanistically support our findings of increased leak in LCR. LCR rats had significantly higher incidence of ventricular fibrillation. CONCLUSION Selection of inborn low aerobic capacity over generations leads to a phenotype with increased risk of ventricular fibrillation. Increased phosphorylation of CaMKII at serine 2814 at the cardiac ryanodine receptor appears as an important mechanism of impaired Ca(2+) handling and diastolic Ca(2+) leak that results in increased susceptibility to ventricular fibrillation.
Collapse
Affiliation(s)
- M. A. Høydal
- K.G. Jebsen Center of Exercise in Medicine; Trondheim Norway
- Department of Circulation and Medical Imaging; Faculty of Medicine; Norwegian University of Science and Technology; Trondheim Norway
- Norwegian Council on Cardiovascular Disease; Oslo Norway
| | - T. O. Stølen
- K.G. Jebsen Center of Exercise in Medicine; Trondheim Norway
- Department of Circulation and Medical Imaging; Faculty of Medicine; Norwegian University of Science and Technology; Trondheim Norway
- Norwegian Council on Cardiovascular Disease; Oslo Norway
| | - A. B. Johnsen
- K.G. Jebsen Center of Exercise in Medicine; Trondheim Norway
- Department of Circulation and Medical Imaging; Faculty of Medicine; Norwegian University of Science and Technology; Trondheim Norway
| | - M. Alvez
- K.G. Jebsen Center of Exercise in Medicine; Trondheim Norway
- Department of Circulation and Medical Imaging; Faculty of Medicine; Norwegian University of Science and Technology; Trondheim Norway
| | - D. Catalucci
- Humanitas Clinical and Research Center; Istituto Ricerca Genetica Biomedicina; National Research Council of Italy; Milan Italy
| | - G. Condorelli
- Humanitas Clinical and Research Center; Istituto Ricerca Genetica Biomedicina; National Research Council of Italy; Milan Italy
| | - L. G. Koch
- Department of Anesthesiology; University of Michigan Medical School; Ann Arbor MI USA
| | - S. L. Britton
- Department of Anesthesiology; University of Michigan Medical School; Ann Arbor MI USA
| | - G. L. Smith
- K.G. Jebsen Center of Exercise in Medicine; Trondheim Norway
- Institute of Cardiovascular and Medical Sciences; University of Glasgow; Glasgow UK
| | - U. Wisløff
- K.G. Jebsen Center of Exercise in Medicine; Trondheim Norway
- Department of Circulation and Medical Imaging; Faculty of Medicine; Norwegian University of Science and Technology; Trondheim Norway
| |
Collapse
|
44
|
Bearzi C, Gargioli C, Baci D, Fortunato O, Shapira-Schweitzer K, Kossover O, Latronico MVG, Seliktar D, Condorelli G, Rizzi R. PlGF-MMP9-engineered iPS cells supported on a PEG-fibrinogen hydrogel scaffold possess an enhanced capacity to repair damaged myocardium. Cell Death Dis 2014; 5:e1053. [PMID: 24525729 PMCID: PMC3944231 DOI: 10.1038/cddis.2014.12] [Citation(s) in RCA: 49] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/07/2013] [Revised: 12/06/2013] [Accepted: 12/12/2013] [Indexed: 01/08/2023]
Abstract
Cell-based regenerative therapies are significantly improved by engineering allografts to express factors that increase vascularization and engraftment, such as placental growth factor (PlGF) and matrix metalloproteinase 9 (MMP9). Moreover, the seeding of therapeutic cells onto a suitable scaffold is of utmost importance for tissue regeneration. On these premises, we sought to assess the reparative potential of induced pluripotent stem (iPS) cells bioengineered to secrete PlGF or MMP9 and delivered to infarcted myocardium upon a poly(ethylene glycol)-fibrinogen scaffold. When assessing optimal stiffness of the PEG-fibrinogen (PF) scaffold, we found that the appearance of contracting cells after cardiogenic induction was accelerated on the support designed with an intermediate stiffness. Revascularization and hemodynamic parameters of infarcted mouse heart were significantly improved by injection into the infarct of this optimized PF scaffold seeded with both MiPS (iPS cells engineered to secrete MMP9) and PiPS (iPS cells engineered to secrete PlGF) cells as compared with nonengineered cells or PF alone. Importantly, allograft-derived cells and host myocardium were functionally integrated. Therefore, survival and integration of allografts in the ischemic heart can be significantly improved with the use of therapeutic cells bioengineered to secrete MMP9 and PlGF and encapsulated within an injectable PF hydrogel having an optimized stiffness.
Collapse
Affiliation(s)
- C Bearzi
- 1] Istituto Ricovero Cura Carattere Scientifico MultiMedica, Milan, Italy [2] Cell Biology and Neurobiology Institute, National Research Council of Italy (CNR), Rome, Italy
| | - C Gargioli
- Istituto Ricovero Cura Carattere Scientifico MultiMedica, Milan, Italy
| | - D Baci
- Istituto Ricovero Cura Carattere Scientifico MultiMedica, Milan, Italy
| | - O Fortunato
- Istituto Ricovero Cura Carattere Scientifico MultiMedica, Milan, Italy
| | - K Shapira-Schweitzer
- Faculty of Biomedical Engineering, Technion-Israel Institute of Technology, Haifa, Israel
| | - O Kossover
- Faculty of Biomedical Engineering, Technion-Israel Institute of Technology, Haifa, Israel
| | - M V G Latronico
- Humanitas Clinical and Research Center, Rozzano, Milan, Italy
| | - D Seliktar
- Faculty of Biomedical Engineering, Technion-Israel Institute of Technology, Haifa, Israel
| | - G Condorelli
- Humanitas Clinical and Research Center, Rozzano, Milan, Italy
| | - R Rizzi
- 1] Istituto Ricovero Cura Carattere Scientifico MultiMedica, Milan, Italy [2] Cell Biology and Neurobiology Institute, National Research Council of Italy (CNR), Rome, Italy
| |
Collapse
|
45
|
Di Pasquale E, Lodola F, Miragoli M, Denegri M, Avelino-Cruz JE, Buonocore M, Nakahama H, Portararo P, Bloise R, Napolitano C, Condorelli G, Priori SG. CaMKII inhibition rectifies arrhythmic phenotype in a patient-specific model of catecholaminergic polymorphic ventricular tachycardia. Cell Death Dis 2013; 4:e843. [PMID: 24113177 PMCID: PMC3824678 DOI: 10.1038/cddis.2013.369] [Citation(s) in RCA: 87] [Impact Index Per Article: 7.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/02/2013] [Revised: 07/25/2013] [Accepted: 07/29/2013] [Indexed: 12/12/2022]
Abstract
Induced pluripotent stem cells (iPSC) offer a unique opportunity for developmental studies, disease modeling and regenerative medicine approaches in humans. The aim of our study was to create an in vitro 'patient-specific cell-based system' that could facilitate the screening of new therapeutic molecules for the treatment of catecholaminergic polymorphic ventricular tachycardia (CPVT), an inherited form of fatal arrhythmia. Here, we report the development of a cardiac model of CPVT through the generation of iPSC from a CPVT patient carrying a heterozygous mutation in the cardiac ryanodine receptor gene (RyR2) and their subsequent differentiation into cardiomyocytes (CMs). Whole-cell patch-clamp and intracellular electrical recordings of spontaneously beating cells revealed the presence of delayed afterdepolarizations (DADs) in CPVT-CMs, both in resting conditions and after β-adrenergic stimulation, resembling the cardiac phenotype of the patients. Furthermore, treatment with KN-93 (2-[N-(2-hydroxyethyl)]-N-(4methoxybenzenesulfonyl)]amino-N-(4-chlorocinnamyl)-N-methylbenzylamine), an antiarrhythmic drug that inhibits Ca(2+)/calmodulin-dependent serine-threonine protein kinase II (CaMKII), drastically reduced the presence of DADs in CVPT-CMs, rescuing the arrhythmic phenotype induced by catecholaminergic stress. In addition, intracellular calcium transient measurements on 3D beating clusters by fast resolution optical mapping showed that CPVT clusters developed multiple calcium transients, whereas in the wild-type clusters, only single initiations were detected. Such instability is aggravated in the presence of isoproterenol and is attenuated by KN-93. As seen in our RyR2 knock-in CPVT mice, the antiarrhythmic effect of KN-93 is confirmed in these human iPSC-derived cardiac cells, supporting the role of this in vitro system for drug screening and optimization of clinical treatment strategies.
Collapse
Affiliation(s)
- E Di Pasquale
- Istituto di Ricerca Genetica e Biomedica, National Research Council of Italy, Milan, Italy
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
46
|
Cavarretta E, Chiariello GA, Condorelli G. Platelets, endothelium, and circulating microRNA-126 as a prognostic biomarker in cardiovascular diseases: per aspirin ad astra. Eur Heart J 2013; 34:3400-2. [DOI: 10.1093/eurheartj/eht032] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/19/2023] Open
|
47
|
Altman M, Bergerot C, Thibault H, Aussoleil A, Skuldadt Davidsen E, Barthelet M, Derumeaux GA, Grapsa J, Zimbarra Cabrita I, Afilalo J, Paschou S, Dawson D, Durighel G, O'regan D, Howard L, Gibbs J, Nihoyannopoulos P, Morenate Navio M, Mesa Rubio M, Ortega MD, Ruiz Ortiz M, Castillo Bernal F, Del Pino CL, Toledano F, Alvarez-Ossorio MP, Ojeda Pineda S, Lezo Cruz-Conde JSD, Jasaityte R, Claus P, Teske A, Herbots L, Verheyden B, Rademakers F, D'hooge J, Tocchetti CG, Coppola C, Rea D, Quintavalle C, Guarino L, Castaldo N, De Lorenzo C, Condorelli G, Arra C, Maurea N, Voilliot D, Huttin O, Camara Y, Djaballah W, Carillo S, Zinzius P, Sellal J, Angioi M, Juilliere Y, Selton-Suty C, Dobrowolski P, Klisiewicz A, Florczak E, Prejbisz A, Szwench E, Rybicka J, Januszewicz A, Hoffman P, Jurado Roman A, De Dios Perez S, De Nicolas JMM, Diaz Anton B, Rubio Alonso B, Martin Asenjo R, Mayordomo Gomez S, Villagraz Tecedor L, Blazquez L, De Meneses RT, Bernard A, Hernandez AI, Reynaud A, Lerclercq C, Daubert J, Donal E, Arjan Singh R, Sivarani S, Lim S, Azman W, Almeida M, Cardim N, Fonseca V, Carmelo V, Santos S, Santos T, Toste J, Kosmala W, Orda A, Karolko B, Mysiak A, Przewlocka-Kosmala M, Farsalinos K, Tsiapras D, Kyrzopoulos S, Avramidou E, Vassilopoulou D, Voudris V, Hayrapetyan H, Adamyan K, Jurado Roman A, De Dios Perez S, Rubio Alonso B, De Nicolas JMM, Diaz Anton B, Martin Asenjo R, Montero Cabezas J, Granda Nistal C, Garcia Aranda B, Sanchez Sanchez V, Sestito A, Lamendola P, Di Franco A, Lauria C, Lanza G, Kukucka M, Unbehaun A, Buz S, Mladenow A, Kuppe H, Pasic M, Habazettl H, Gemma D, Montoro Lopez N, De Celix MGR, Lopez Fernandez T, De Torres Alba F, Del Valle DI, Ramirez U, Mesa J, Moreno Yanguela M, Lopez Sendon J, Eveborn GW, Schirmer H, Lunde P, Heggelund G, Rasmussen K, Wang Z, Lasota B, Mizia-Stec K, Mizia M, Chmiel A, Adamczyk T, Chudek J, Gasior Z, Venkatesh A, Johnson J, Sahlen A, Brodin L, Winter R, Shahgaldi K, Manouras A, Valbuena S, Iniesta A, Lopez T, De Torres F, Salinas P, Garcia S, Ramirez U, Mesa J, Moreno M, Lopez-Sendon J, Lebid I, Kobets T, Kuzmenko T, Katsanos S, Yiu K, Clavel M, Nina Ajmone N, Van Der Kley F, Rodes Cabau J, Schalij M, Bax J, Pibarot P, Delgado V, Fusini L, Tamborini G, Muratori M, Gripari P, Marsan N, Cefalu' C, Ewe S, Maffessanti F, Delgado V, Pepi M, Hasselberg N, Haugaa K, Petri H, Berge K, Leren T, Bundgaard H, Edvardsen T, Ancona R, Comenale Pinto S, Caso P, Coppola M, Rapisarda O, Cavallaro C, Vecchione F, D'onofrio A, Calabro' R, Rimbas R, Mihaila S, Enescu O, Patrascu N, Dragoi R, Rimbas M, Pop C, Vinereanu D, Gustafsson S, Morner S, Gronlund C, Suhr O, Lindqvist P, Di Bella G, Zito C, Minutoli F, Madaffari A, Cusma Piccione M, Mazzeo A, Massimo R, Pasquale M, Vita G, Carerj S, Rangel I, Goncalves A, Sousa C, Correia A, Martins E, Silva-Cardoso J, Macedo F, Maciel M, Pfeiffer B, Rigopoulos A, Seggewiss H, Alvarez Fuente M, Sainz Costa T, Medrano C, Navarro M, Blazquez Gamero D, Ramos J, Mellado M, De Jose M, Munoz M, Maroto E, Gargani L, Gosciniak P, Pratali L, Agoston G, Bruni C, Guiducci S, Matucci Cerinic M, Varga A, Sicari R, Picano E, Yiu K, Zhao C, Mei M, Yeung C, Siu C, Tse H, Florescu M, Enescu O, Magda L, Mincu R, Vinereanu D, Daha I, Stanescu CM, Chirila L, Baicus C, Vlase A, Dan G, Montoro Lopez M, Florez Gomez R, Alonso Ladreda A, Itziar Soto C, Rios Blanco J, Gemma D, De Torres Alba F, Moreno Yanguela M, Lopez Sendon J, Guzman Martinez G, Lichodziejewska B, Kurnicka K, Goliszek S, Kostrubiec M, Dzikowska-Diduch O, Ciurzynski M, Labyk A, Krupa M, Palczewski P, Pruszczyk P, De Sousa CC, Rangel I, Correia A, Martins E, Vigario A, Pinho T, Silva Cardoso J, Goncalves A, Macedo F, Maciel M, Park SJ, Song JE, Lee YJ, Ha MR, Chang SA, Choi JO, Lee SC, Park S, Oh J, Van De Bruaene A, De Meester P, Buys R, Vanhees L, Delcroix M, Voigt J, Budts W, Blundo A, Buccheri S, Monte IP, Leggio S, Tamburino C, Sotaquira M, Fusini L, Maffessanti F, Pepi M, Lang R, Caiani E, Floria M, De Roy L, Xhaet O, Blommaert D, Jamart J, Gerard M, Deceuninck O, Marchandise B, Seldrum S, Schroeder E, Unsworth B, Sohaib S, Kulwant-Kaur K, Malcolme-Lawes L, Kanagaratnam P, Malik I, Ren B, Mulder H, Haak A, Van Stralen M, Szili-Torok T, Pluim J, Geleijnse M, Bosch J, Baglini R, Amaducci A, D'ancona G, Van Den Oord S, Akkus Z, Bosch J, Ten Kate G, Renaud G, Sijbrands E, De Jong N, Van Der Lugt A, Van Der Steen A, Schinkel A, Bjallmark A, Larsson M, Grishenkov D, Brodin LA, Brismar T, Paradossi G, Sveen KA, Nerdrum T, Hanssen K, Dahl-Jorgensen K, Steine K, Cimino S, Pedrizzetti G, Tonti G, Canali E, Petronilli V, Cicogna F, Arcari L, De Luca L, Iacoboni C, Agati L, Abdel Moneim SS, Eifert Rain S, Bernier M, Bhat G, Hagen M, Bott-Kitslaar D, Castello R, Wilansky S, Pellikka P, Mulvagh S, Delithanasis I, Celutkiene J, Kenny C, Monaghan M, Park W, Hong G, Son J, Lee S, Kim U, Park J, Shin D, Kim Y, Toutouzas K, Drakopoulou M, Aggeli C, Felekos I, Nikolaou C, Synetos A, Stathogiannis K, Tsiamis E, Siores E, Stefanadis C, Plicht B, Kahlert P, Grave T, Buck T, Konorza T, Gursoy M, Gokdeniz T, Astarcioglu M, Bayram Z, Cakal B, Karakoyun S, Kalcik M, Acar R, Kahveci G, Ozkan M, Maffessanti F, Tamborini G, Tsang W, Weinert L, Gripari P, Fusini L, Muratori M, Caiani E, Lang R, Pepi M, Yurdakul S, Avci B, Sahin S, Dilekci B, Aytekin S, Ancona R, Comenale Pinto S, Caso P, Arenga F, Coppola M, Rapisarda O, Calabro' R, Hascoet S, Martin R, Dulac Y, Peyre M, Benzouid C, Hadeed K, Acar P, Celutkiene J, Zakarkaite D, Skorniakov V, Zvironaite V, Grabauskiene V, Burca J, Ciparyte L, Laucevicius A, Di Salvo G, Rea A, D'aiello A, Del Gaizo F, Pergola V, D'andrea A, Caso P, Pacileo G, Calabro R, Russo M, Dedobbeleer C, Hadefi A, Naeije R, Unger P, Mornos C, Cozma D, Ionac A, Mornos A, Valcovici M, Pescariu S, Petrescu L, Hu K, Liu D, Niemann M, Herrmann S, Cikes M, Stoerk S, Knop S, Ertl G, Bijnens B, Weidemann F, De Knegt M, Biering-Sorensen T, Sogaard P, Sivertsen J, Jensen J, Mogelvang R, Dedobbeleer C, Hadefi A, Unger P, Naeije R, Lam W, Tang M, Chan K, Yang Y, Fang F, Sun J, Yu C, Lam Y, Panoulas V, Sulemane S, Bratsas A, Konstantinou K, Nihoyannopoulos P, Cimino S, Canali E, Petronilli V, Cicogna F, Arcari L, De Luca L, Francone M, Iacoboni C, Agati L, Schau T, Seifert M, Ridjab D, Schoep M, Gottwald M, Neuss M, Meyhoefer J, Zaenker M, Butter C, Tarr A, Stoebe S, Pfeiffer D, Hagendorff A, Maret E, Ahlander BM, Bjorklund PG, Engvall J, Staskiewicz G, Czekajska-Chehab E, Adamczyk P, Siek E, Przybylski P, Maciejewski R, Drop A, Jimenez Rubio C, Isasti Aizpurua G, Miralles Ibarra J, Al-Mallah M, Somg T, Alam S, Chattahi J, Zweig B, Dhanalakota K, Boedeker S, Ananthasubramaniam K, Park C, March K, Jones S, Mayet J, Tillin T, Chaturvedi N, Hughes A, Hamodraka E, Kallistratos E, Karamanou A, Tsoukas T, Mavropoulos D, Kouremenos N, Zaharopoulou I, Nikolaidis N, Kremastinos D, Manolis A, Loboz-Rudnicka M, Jaroch J, Bociaga Z, Kruszynska E, Ciecierzynska B, Dziuba M, Dudek K, Uchmanowicz I, Loboz-Grudzien K, Silva D, Magalhaes A, Jorge C, Cortez-Dias N, Carrilho-Ferreira P, Silva Marques J, Portela I, Pascoa C, Nunes Diogo A, Brito D, Roosens B, Bala G, Droogmans S, Hostens J, Somja J, Delvenne E, Schiettecatte J, Lahoutte T, Van Camp G, Cosyns B. Poster Session: Right ventricular systolic function. Eur Heart J Cardiovasc Imaging 2012. [DOI: 10.1093/ehjci/jes268] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
48
|
Quintavalle C, Donnarumma E, Iaboni M, Roscigno G, Garofalo M, Romano G, Fiore D, De Marinis P, Croce CM, Condorelli G. Effect of miR-21 and miR-30b/c on TRAIL-induced apoptosis in glioma cells. Oncogene 2012; 32:4001-8. [PMID: 22964638 DOI: 10.1038/onc.2012.410] [Citation(s) in RCA: 90] [Impact Index Per Article: 7.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/28/2012] [Revised: 06/13/2012] [Accepted: 07/23/2012] [Indexed: 12/27/2022]
Abstract
Glioblastoma is the most frequent brain tumor in adults and is the most lethal form of human cancer. Despite the improvements in treatments, survival of patients remains poor. To define novel pathways that regulate susceptibility to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in glioma, we have performed genome-wide expression profiling of microRNAs (miRs). We show that in TRAIL-resistant glioma cells, levels of different miRs are increased, and in particular, miR-30b/c and -21. We demonstrate that these miRs impair TRAIL-dependent apoptosis by inhibiting the expression of key functional proteins. T98G-sensitive cells treated with miR-21 or -30b/c become resistant to TRAIL. Furthermore, we demonstrate that miR-30b/c and miR-21 target respectively the 3' untranslated region of caspase-3 and TAp63 mRNAs, and that those proteins mediate some of the effects of miR-30 and -21 on TRAIL resistance, even in human glioblastoma primary cells and in lung cancer cells. In conclusion, we show that high expression levels of miR-21 and -30b/c are needed to maintain the TRAIL-resistant phenotype, thus making these miRs as promising therapeutic targets for TRAIL resistance in glioma.
Collapse
Affiliation(s)
- C Quintavalle
- Department of Cellular and Molecular Biology and Pathology, 'Federico II' University of Naples, Naples, Italy
| | | | | | | | | | | | | | | | | | | |
Collapse
|
49
|
Garofalo M, Quintavalle C, Romano G, Croce CM, Condorelli G. miR221/222 in cancer: their role in tumor progression and response to therapy. Curr Mol Med 2012; 12:27-33. [PMID: 22082479 DOI: 10.2174/156652412798376170] [Citation(s) in RCA: 263] [Impact Index Per Article: 21.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/05/2011] [Revised: 07/29/2011] [Accepted: 08/23/2011] [Indexed: 12/12/2022]
Abstract
miRNAs are small non-coding RNAs of ~24 nt that can block mRNA translation and/or negatively regulate its stability. There is a large body of evidence that dysregulation of miRNAs is a hallmark of cancer. miRNAs are often aberrantly expressed and their function is linked to the regulation of oncogenes and/or tumor suppressor genes involved in cell signaling pathway. miR-221 and miR-222 are two highly homologous microRNAs, whose upregulation has been recently described in several types of human tumors. miR-221/222 have been considered to act as oncogenes or tumor suppressors, depending on tumor system. Silencing oncomiRs or gene therapy approaches, based on re-expression of miRNAs that are down-regulated in cancer cells, could represent a novel anti-tumor approach for integrated cancer therapy. Here we will review the role of miR-221/222 in cancer progression and their use as prognostic and therapeutic tools in cancer.
Collapse
Affiliation(s)
- M Garofalo
- Department of Molecular Virology, Immunology and Medical Genetics, Comprehensive Cancer Center, Ohio State University, Columbus, OH, USA
| | | | | | | | | |
Collapse
|
50
|
Norata GD, Pinna C, Zappella F, Elia L, Sala A, Condorelli G, Catapano AL. MicroRNA 143-145 deficiency impairs vascular function. Int J Immunopathol Pharmacol 2012; 25:467-74. [PMID: 22697078 DOI: 10.1177/039463201202500216] [Citation(s) in RCA: 27] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
Abstract
MicroRNAs are required for vascular smooth muscle growth, differentiation and function. MiR143-145 modulates cytoskeletal dynamics and acquisition of the contractile phenotype by smooth muscle cells. Lack of this miRNA cluster results in decreased blood pressure and reduced vasocontraction. As all these observations point to a key role for miR143-145 in the vasculature, we investigated whether miR143-145 deficiency is associated with impaired vascular tone. Vasocontraction was assessed in isolated aortic rings from miR143-145 KO and wild type animals incubated with increasing concentrations of phenylephrine (10(-9)M to 10(-5)M) or KCl 0.3M. In both cases, aortic vessel contraction was dramatically reduced in miR143-145 KO animals compared to controls. Next, aortic rings were pre-contracted with phenylephrine (EC60: 10(-7)M) and concentration responses for acetylcholine were obtained. A significantly reduced vasodilation was observed in miR143-145 KO animals compared to controls and similar results were obtained when an exogenous donor of nitric oxide (sodium nitroprusside) was used. Endothelial nitric oxide synthase or guanylate cyclase mRNA expression were not different between the animal groups thus suggesting to investigate the effect of other vasodilators. Isoprenaline mediated vasodilation was significantly reduced in miR143-145 KO animals compared to controls in the absence or in the presence of the guanylate cyclase inhibitor ODQ (10(-4)M), suggesting that also beta adrenergic vasodilation is impaired following miR143-145 deficiency. Finally, the effect of a stable mimetic prostacyclin, namely iloprost, was investigated and again a reduced vasodilation was observed in miR143-145 KO animals. MiR143-145 deficiency is associated not only with altered vasocontraction but also with impaired vasodilation, which probably reflects the impaired VSMC differentiation phenotype reported in miR143-145 KO animals.
Collapse
Affiliation(s)
- G D Norata
- Department of Pharmacological Sciences, Università degli Studi di Milano, Milan, Italy.
| | | | | | | | | | | | | |
Collapse
|